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1. Introduction  
 
1.1. Synthetic cannabinoid receptor agonists (SCRA) are chemicals that stimulate 
the endogenous cannabinoid receptors within the body responsible for 
mediating the pharmacological effects of tetrahydrocannabinol (THC), the 
major active ingredient of cannabis. They are sometimes referred to as 
synthetic cannabinoids, but this term is misleading, as some examples are 
not structurally related to naturally occurring cannabinoid compounds. The 
first examples of SCRA were created in the 1980s to research cannabinoid 
receptor pharmacology and to explore the therapeutic potential of drugs 
interacting with the cannabinoid receptor system.  
 
1.2. Due to the increased online availability of published research studies and 
patents describing their synthesis [Norman et al., 2020], recreational use of 
these compounds was commercialised in Europe in the mid-2000s and in the 
United States of America (USA) in late-2000s [White, 2017; EMCDDA, 
2018a]. SCRA were previously sold openly in the UK by high street retail 
outlets, often referred to as ‘head shops’. These products, typically consisting 
of inert herbal materials infused or sprayed with SCRA, are often generally 
referred to as ‘spice’, with specific products sold in attractive packaging using 
brand names such as K2, Mamba, Annihilation, Pandora’s Box, Clockwork 
Orange and Kronic, as well as Spice [NEPTUNE, 2015; Waugh et al 2016; 
Norman et al., 2020]. As of March 2020, there have been nearly 700 different 
SCRA brand and street names identified worldwide [Spice Addiction Support, 
2020]. These compounds have been amongst the most common types of 
novel psychoactive substances (NPS) encountered in the UK and elsewhere 
over the last decade. 
 
1.3. Many specific examples of SCRA were controlled in the UK by legislation 
introduced in 2009, 2012 and 2016 (see below). However, the numbers of 
different substances and their chemical complexity allow medicinal chemists 
to synthesise examples that evade legislation based on chemical structure. 
As of August 2020, almost 200 different SCRA compounds had been 
identified analytically in Europe and reported to the EMCDDA. There are 
many further opportunities for structural modifications and the potential for 
many further analogues to appear in the future [Potts et al., 2020]. 
 
1.4. The enactment of the Psychoactive Substances Act (PSA) in May 2016 has 
prohibited the production and supply of psychoactive materials, including 
SCRA, removing their open sale and significantly reducing general population 
use [Home Office, 2018]. Whilst there is evidence to suggest that recreational 
use has declined since 2016, prevalence of use in specific user sub-groups 
has remained high and there have been media reports of ‘spice epidemics’ in 
major UK cities and prisons [Gray et al., 2020]. These substances have 
developed a reputation as powerful and cheap intoxicants among vulnerable 
groups, such as the homeless and prisoners, who use them in part for their 
‘mind-numbing’ effects [EMCDDA, 2018b; Gray et al., 2020]. 
 
1.5. In November 2018, the possibility of reclassification of SCRA was debated in 
Parliament and the then Minister for Policing and the Fire Service committed 
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to seeking advice on this issue from the Advisory Council on the Misuse of 
Drugs (ACMD). This advice was commissioned in February 2019 and 
requested the ACMD to provide: 
 
1. An updated harms assessment to the ACMD’s previous reports on 
synthetic cannabinoids and provide necessary advice on this issue. 
2. A recommendation on whether the current classification under the 
Misuse of Drugs Act 1971 (MDA) and the schedule under the Misuse 
of Drugs Regulations 2001 (MDR) of synthetic cannabinoids is 
appropriate.  
3. If not appropriate, a recommendation on whether all or some synthetic 
cannabinoids should be moved to a different classification or 
schedule.  
 
1.6. The ACMD has therefore compiled this report, which examines evidence that 
has emerged since it last provided advice on the harms of SCRA. For the 
purposes of the report, the ACMD conducted a literature review of papers 
submitted since 2012, as this was the last time a harms assessment was 
conducted on this drug group.  
 
2. Previous ACMD advice and legal status of SCRA in the 
UK 
 
2.1. In July 2009, the ACMD submitted a report on major cannabinoid agonists 
[ACMD, 2009]. Although only a small number of compounds were forensically 
identified in the then legally available ‘spice’, the ACMD recommended that a 
generic definition should be used to control SCRA under the MDA in order to 
prevent illicit manufactures utilising the range of chemically different but 
functionally similar major cannabinoid agonists. The ACMD proposed five 
generic definitions for SCRA, based on the published research of JW 
Huffman’s research team, and listed five additional substances by name (HU-
210, Nabilone, WIN-55212-2, HU-243, and CP 50,556-1). Following this 
advice, these ‘first generation’ cannabinoids were controlled as Class B under 
the MDA and placed under Schedule 1 of the MDR at the end of 2009. 
 
2.2. In 2012, prompted by evidence that gaps in the definition were being 
exploited, the ACMD provided further advice to expand the generic definition 
for SCRA and confirmed that class B under the MDA and schedule 1 of the 
MDR remained appropriate [ACMD, 2012]. These ‘second generation’ 
compounds were controlled in early 2013. 
 
2.3. Evidence of harmful SCRA that fell outside of the generic definition in the 
MDA subsequently began to emerge. The ACMD responded by publishing a 
further report in November 2014 to recommend a broad ‘third generation’ 
SCRA generic definition. The 2014 review reported effects of new materials 
that had similar or more potent effects than those materials already 





2.4. Compounds captured by the ‘third generation’ generic definition were 
controlled as Class B Schedule 1 substances in December 2016. However, 
due to the broad nature of the generic definition, some compounds without 
psychoactive effects were unintentionally captured under this definition, 
inadvertently subjecting them to strict controls. In December 2017, the ACMD 
provided follow up advice, to address concerns that the broad definition was 
creating barriers to therapeutic research [ACMD, 2017]. It was recommended 
that the scope of the ‘third generation’ definition should be reduced to remove 
many of the compounds from the definition that were unintentionally caught 
from the original definition. The suggested amendments were applied in 
November 2019 [Home Office, 2019] and consequently, research was 
permitted on the excluded compounds without the requirement for a Home 
Office licence. It should be noted, however, that some compounds without 
cannabinoid receptor agonist activity, are still captured by the updated 
generic definition. 
 
2.5. Over the past decade, the ACMD has intermittently considered the available 
evidence on this drug group. Despite a gradual expansion of the generic 
definition with each ‘generation’, the ACMD has previously advised that Class 
B under the MDA and Schedule 1 of the MDR remained an appropriate 
measure of control. The main harms evidenced in these reports that qualified 
SCRA for Class B level of control include:  
 
• reports of emergency room presentations in Germany for psychosis-
like panic attacks, heart and circulatory problems; 
• anecdotal user reports of severe adverse effects, including increased 
heart rate, panic attacks and convulsions; 
• cannabinoid-related toxicity causing tachycardia, agitation, 
drowsiness, vomiting, hallucinations and nausea; and 
• acute withdrawal associated with cessation of long-term use of these 
products suggesting that their use may be associated with 
dependence. 
 
2.6. The harms associated with this diverse drug group detailed in previous ACMD 
reports were largely ‘potential harms’ because:  
• much less analytical information was available;  
• the physical harms of SCRA use were not well documented; and,  
• limited evidence of social harms was available at the time of 
publication.  
3. Chemistry, nomenclature and pharmacology 
 
3.1. SCRA are complex molecules and there are large numbers of specific 
examples. The chemical structures of SCRA fall into four distinct groups: 
 
1. Compounds with structures related to THC are named individually 
in the MDA or covered as a cannabinol derivative. e.g. Nabilone, HU-
210, HU-243, CP 50,556-1 (Levonantradol). 
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2. Cyclohexylphenols, which are covered by a generic definition in the 
MDA.  
3. Compounds structurally related to JWH-018 which are covered by 
generic definitions in the MDA. 
4. Compounds with similar structures to those in group 3 but which 
cannot easily be included in a generic definition and are therefore 
named individually in the MDA, for example WIN-55,212-2. 
 
3.2. In 2011, the EMCDDA developed alpha-numeric systematic abbreviated 
names to describe compounds structurally related to JWH-018, utilising a 
four-group pharmacophore model [Shevyrin et al 2016] that comprises ‘core’, 
‘tail’, ‘linker’ and ‘linked’ (aka ‘head’ or ‘secondary structure’) groups 
[EMCDDA, 2017; Potts et al., 2020]. Where possible, EMCDDA nomenclature 
has been used in this report (see Annex D). 
 
3.3. Different systems of nomenclature have been used to refer to the same 
substance and this can produce confusion. Some SCRA can be described 
using non-systematic abbreviated alphanumeric names such as AKB-48, 
2NE1 and XLR-11. Others use a code to represent the company or person 
responsible for their original discovery, followed by a number that identifies 
the specific compound, for example the ‘WIN-’, ‘HU-’, ‘CP-’,‘JWH-’ and ‘AM-’ 
series of compounds. This system identifies the originator laboratory, but the 
number provides no information about the chemical structure or 
pharmacological properties.  
 
3.4. Chemical structures can be described very precisely using the International 
Union of Pure and Applied Chemistry (IUPAC) nomenclature, but the names 
generated are complex and unwieldy for general use. An example is (2S)-2-
([1-(cyclohexylmethyl)-1H-indol-3-yl]formamido)- 3,3-dimethylbutanoate, a 
compound that is also referred to using the EMCDDA’s simpler alpha-numeric 
systematic abbreviated name MDMB-CHMICA [Potts et al 2020].  
 
3.5. Most SCRA affect both type 1 and type 2 cannabinoid receptors (CB1 and 
CB2) but to different degrees. SCRA typically act as full agonists at CB1 and 
CB2 receptors and can therefore produce more pronounced effects than their 
naturally occurring counterpart THC, which is only a partial agonist at CB1 and 
CB2 receptors [Atwood et al., 2011; Ligresti et al 2016; Akram et al., 2019]. 
Activity at the CB1 receptor produces the intoxicating effects sought by users 
and the SCRA entering the NPS market are those with structures that target 
this receptor. There is evidence that more recently encountered ‘third-
generation’ SCRA that have come to dominate the UK market, such as 5F-
MDMB-PINACA and AMB-FUBINACA are more potent agonists at CB1 
receptors than those previously encountered, for example, JWH-018 [Banister 
et al., 2016; Antonides, 2019]. 
 
3.6. Limited information is available on the human pharmacology of SCRA. A 
controlled administration study demonstrated that inhalation of 2mg or 3mg of 
the first-generation compound JWH-018 was tolerated by recreational 
cannabis users, while producing some impairment in cognitive functioning. 
The maximum reported ‘high’ occurred one hour after inhalation [Theunissen 
et al., 2018]. A second study revealed variable subjective responses to higher 
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doses of JWH-018, with some people reporting no subjective intoxication and 
others maximal subjective intoxication. Those with more pronounced 
intoxication had higher serum drug concentrations; indicating variability in the 
drug delivery by inhalation. The study demonstrated that doses as low as 
2mg can induce unpredictable psychological effects that vary from weak to 
moderate. Successive inhalations from a given mixture may therefore 
provoke sudden and unexpected levels of impairment and increase the risk of 
overdosing [Theunissen et al., 2019].  
4. Clinical and legitimate uses  
 
4.1. A consultation with the Medicines and Healthcare products Regulatory 
Agency (MHRA) confirmed that there are some cannabis-based medicinal 
products licenced and available for therapeutic use in the UK (e.g. Epidyolex 
[EMC, 2020a] and Sativex [EMC, 2020b]). The only synthetic material which 
affects the CB1 receptor that is currently licenced as a medicinal product is 
Nabilone. This is prescribed under close medical supervision (preferably in a 
hospital setting) to treat nausea and vomiting caused by cytotoxic 
chemotherapy, if the patient is unresponsive to conventional antiemetics 
[British National Formulary, 2020]. Due to its risk of diversion as a THC 
analogue, Nabilone is controlled as an individually named product under the 
MDA (Class B) and is a Schedule 2 material under the MDR.  
 
The MHRA does not hold any records of unlicensed SCRA products being 
imported for named patient prescriptions (as of June 2020). Also at this time 
there were no clinical trials identified on the European Union (EU) clinical 
trials register involving SCRA compounds that were either named individually 
or captured by the SCRA generic definitions in the MDA. 
 
5. Illicit use and supply  
 
5.1. Smoking, inhalation, insufflation, and ingestion are the main ways in which 
SCRA are used [White, 2017]. Pure compounds are in powder form at room 
temperature, but these powders are dissolved in solvent and then sprayed on 
inert plant material or a sheet of paper which is then smoked. Preparing 
SCRA in this form can lead to spots of high concentrations on the paper, 
causing inconsistent dosing during administration and leading to significant 
risk to the user. Other methods of administration include vaporising (‘vaping’) 
SCRA liquid solutions using an e-cigarette and ingestion of pills or powders 
[Peacock et al., 2019; Norman et al., 2020]. Prisoners have been known to 
use e-cigarettes modified to expose the heating element to smoke SCRA 
impregnated papers as well as using the steam from kettles to evaporate the 
compound for inhalation.  
 
5.2. Multiple types of SCRA, in a variety of forms (herbal, papers, powder, liquids) 
have appeared in UK markets, but there is no evidence to suggest that SCRA 
are being manufactured in the UK. Forensic analysis has determined that 
most SCRA material seized originates from China. Supply is primarily 
imported through Fast Parcel and post modes, with links to some organised 
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crime groups arranging importation into the UK via Europe alongside other 
controlled substances.  
 
5.3. The UK SCRA market has evolved to favour different iterations of novel 
SCRA compounds over time. Disappearances of specific SCRA from seizures 
have been linked to legislative changes in China [Norman et al., 2020], 
evidencing further that SCRA encountered in the UK are imported rather than 
manufactured in the UK. In a study of prison seizures in Scotland, Norman et 
al [2020] found a shift in the prevalence of commonly encountered 
compounds from 5F-MDMB-PINACA (5F-ADB) and AMB-FUBINACA to 5F-
MDMB-PICA and 4F-MDMB-BINACA in late 2018, in line with the State 
Council of China bringing these two SCRA (along with six others) under 
legislative control on 29 August 2018 (see Annex A).  
 
5.4. SCRA are likely to be distributed regionally through a process called 
‘community deal’ whereby one user visits a main dealer to buy drugs and then 
distributes purchased products to others. As of March 2020, SCRA were 
priced at £10 a gram, with £5 deals also widely accessible. In a custodial 
setting, the cost is expected to be 10 times higher than the street value, but 
this will vary from prison to prison. Like other controlled substances, SCRA 
are smuggled into prisons using drones, corrupt prison staff or prisoners 
hiding items within body orifices when entering the prison.  
 
[paragraph 5.5. has been redacted from the published version of this report] 
6. Prevalence and patterns of use in the UK 
 
6.1. Originally introduced to the UK as a ‘legal high’ with marketing predominantly 
aimed at young people in city centres [Peacock et al., 2019], SCRA use has 
now shifted substantially to rough sleepers and prison populations across the 
UK [Gray et al 2020; Norman et al., 2020]. Levels of use recorded in general 
population surveys remain relatively low when compared with traditional 
illegal substances [Ralphs, 2017a].  
 
6.2. The annual Crime Survey for England and Wales (CSEW) does not explicitly 
report SCRA use but does collect information on the nature of NPS use. Self-
reported NPS use (over the previous 12 months) was measured at 0.9% in 
16– to 59-year olds and 2.8% in 16– to 24-year olds in 2014/15. By 2018/19, 
use had fallen to 0.5% and 1.4% respectively. ‘Herbal smoking mixtures’ 
(likely to contain SCRA) were the most prevalent NPS form used in 2016/17, 
representing 40% of total NPS use. By 2018/19, use of smoking mixtures had 
fallen behind powder, crystals, tablets and ‘other’ types of NPS use, making 
up only 24% of total NPS use [CSEW, 2019]. The Smoking, Drinking and 
Drug Use among Young People in England (SDD) survey does not report 
against SCRA use.  
 
6.3. The Scottish Crime and Justice Survey (SCJS) [2019] has only reported drug 
use in their most recent report (2017/18), which demonstrated that 0.2% of 
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respondents reported SCRA use over the previous 12 months [Scottish Crime 
and Justice Survey, 2019].  
 
6.4. Information on the prevalence of SCRA use was not available in the 
equivalent survey covering Northern Ireland, the All Ireland Drug Prevalence 
Survey [Department of Health Northern Ireland, 2017] as this only provides 
data up until 2015. A pilot drugs module was included in the 2017/18 Northern 
Ireland Health Survey and included a question on last year prevalence of 
usage of New Psychoactive Substances and Synthetic Cannabis, finding less 
than 0.1% in each category [Department of Health Northern Ireland, written 
submission of September 2020].  
 
6.5. Unlike some other NPS, self-reported use of SCRA is very low amongst the 
festival-going population of the UK. In 2018, a sample of 2,250 attendees 
across 11 English festivals were surveyed. Of these, over three quarters 
(78%) reported lifetime use of cannabis and over half (58.2%) reported use 
within the last year. By comparison, self-reported lifetime prevalence of the 
use of spice was 3.6% and use within the last year was 0.7%. [Measham, 
2020].  
 
6.6. Drug treatment services in England have seen a decline in new presentations 
of problematic SCRA use (referred to in the data as ‘predominantly 
cannabinoid’ NPS use). In the reporting year 2015/16 National Drug 
Treatment Monitoring System (NDTMS) reported a peak of 1,024 new 
treatment presentations citing problematic SCRA use (0.74% of total 
treatment population) which fell to 716 (0.54% of total treatment population) in 
the reporting year 2018/19, in line with the enactment of the PSA [PHE 2019]. 
Problematic SCRA use of people currently in treatment saw an increase 
between 2015/16 and 2018/19 in those receiving opioid-related treatment 
(390 patients using SCRA in 2015/16 to 745 in 2018/19), but this trend was 
not reflected in people receiving non-opiate (596 in 2015/16 to 296 in 
2018/19) or alcohol-related treatments (291 in 2015/16 to 163 in 2018/19) 
[PHE, 2016; PHE, 2019].  
 
6.7. The use of SCRA within the homeless population has been documented in 
several studies [Smith and Staton, 2019; Joseph et al 2017, 2019; Ralphs et 
al., 2017b; Manseau et al 2017]. In interviews conducted by Gray et al (2020), 
homeless outreach workers and drop-in staff noted recurrently that the use of 
SCRA was pervasive among their clients, affecting 95 to 99% of their 
homeless clients. Motivations for SCRA use were similar to those for 
traditional drugs, namely to escape from the reality of life on the streets and to 
provide relief from the physical conditions of a street-based lifestyle. Their low 
cost, ease of access and high potency contribute to popularity in the 
homeless population [Gray et al., 2020]. The narratives in this study showed 
that the motivations to use SCRA are distinct from those associated with the 
recreational use of natural cannabis and serve specific functions in the 
context of homelessness. One of these is the exploitative and aggressive 
practices from dealers since the selling of SCRA has moved from the head 




6.8. In 2014, drug use in prisons saw a significant shift from traditional illegal 
substances and diverted medications to SCRA [Ralphs et al., 2017a]. A 2016 
survey of 625 male prisoners across nine prisons in England and Wales 
found that 33% of participants had used spice in the last month, eclipsing 
illicitly produced alcohol (‘hooch’, 15%), cannabis (14%) and heroin (14%) as 
the most common substances used [User Voice, 2016]. Motivations for use 
whilst in custody are a combination of potent effects and the ability to avoid 
detection in urine toxicology [White, 2017; Weinstein et al., 2017; Ralphs et 
al., 2017a; Gray et al., 2020]. Given the high potency of SCRA, their effective 
dose is small and the concentrations of drug and metabolites in urine may be 
very low, making clinical detection more difficult [Cohen et al., 2012]. In 
addition, commercially available on-site testing kits may not detect prevalent 
substances and rapidly become outdated when localised markets shift to 
novel compounds. Although SCRA can be identified by liquid or gas 
chromatography with mass spectrometry, these tests are complex and 
expensive, analytical standards may not be available and most secure units 
do not have access to these methods [Klega and Keehbauch, 2018]. 
 
6.9. In the general population SCRA users are predominantly younger adult males 
who also use other drugs. The Welsh Emerging Drug and Identification of 
Novel Substances (WEDINOS) reported that between 2017 -2019, the age 
range of individuals submitting SCRA samples was 16 to 58 years, with 88% 
being male [WEDINOS, 2020]. The National Poisons Information Service 
(NPIS) has previously published information on those with suspected SCRA 
exposure discussed in telephone enquiries to the NPIS between 2011 and 
2014. Of these, 80% were male; ages ranged from 12 to 78 years with a 
median of 21 years and 37% younger than 18 years of age [Waugh et al 
2016]. 
 
6.10. SCRA-associated deaths registered in England between 2015 and 2019 has 
demonstrated a significant increase in the proportion of decedents in older 
age groups, and a decrease of decedents in the younger age groups (data 
provided by the National Programme on Substance Abuse Deaths [NPSAD]). 
There has also been a shift in the deprivation decile scores of decedents, with 
higher scores (meaning decedent from the least deprived areas) not featuring 
amongst SCRA-associated deaths registered in 2019. This is, however, 
derived from reports received by NPSAD as of February 2020, so may 
represent an incomplete number of death registrations for 2019. 
7. Prevalent SCRA identified in the UK   
 
7.1. Information on the prevalence of specific SCRA compounds in the UK is 
available from studies analysing:  
• submitted drug product (WEDINOS);  
• drug seizures (the Home Office Forensic Early Warning System 
[FEWS], Manchester Drug Analysis and Knowledge Exchange 
[MANDRAKE], Eurofins);  
• test purchases (TICTAC);  
• samples from patients attending hospital with severe toxicity (the 
Identification of Novel Psychoactive Substances [IONA] study); and,  
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• post-mortem analysis (LGC Group and NPSAD).  
 
Details are provided in Annex B. 
 
7.2. Over the last five years, the most commonly reported SCRA in these data 
sets were initially 5F-APINACA (5F-AKB-48) and MDMB-CHMICA (2015 to 
2016), with 5F-MDMB-PINACA (5F-ADB), AMB-FUBINACA (FUB-AMB), and 
5F-PB-22 becoming more prevalent between 2016 and 2018. Since early 
2019 the most prevalent compounds have been 4F-MDMB-BINACA, 5F-
MDMB-PICA and MDMB-4en-PINACA. A quantification study conducted by 
the University of Dundee analysed seized material from Scottish prisons and 
demonstrated a clear change in SCRA prevalence from 5F-MDMB-PINACA 
and AMB-FUBINACA (dominant substances identified until late 2018) to 5F-
MDMB-PICA and 4F-MDMB-BINACA (dominant substances identified in late 
2018 and early 2019) [Norman et al., 2020]. 
 
7.3. All of these compounds are captured by the third-generation SCRA generic 
definition in the MDA and are controlled as Class B substances.   
8. Fourth-generation SCRA 
 
8.1. For the purpose of this report, the term ‘fourth-generation’ refers to SCRA 
which are outside the scope of the current MDA generic definition control.  
 
8.2. Illicit manufacturers continue to explore novel structures that retain CB1 
agonist activity but will evade increasing national and international control on 
known SCRA materials. Since 2016, the EMCDDA have reported 
approximately ten new SCRA identifications within Europe each year. Many 
of these are simple variants of already known materials and are covered 
within the scope of the UK generic controls. However, other more novel 
SCRA, which are outside the UK generic, are also being identified. These 
appear to have been developed from structures rediscovered in published 
patents resulting from pharmaceutical research intended to develop CB1 or 
CB2 active medicinal products.  
 




8.8. As yet, none of the ‘fourth-generation’ materials have been recorded as 
making a significant entry into the UK SCRA market, which continues to be 
dominated by indole and indazole-based materials (see Annex D). There 
remains an ongoing risk that such compounds may emerge, and continuing 
vigilance is important, although as CB1 agonists they would be subject to the 
provisions of the PSA.   
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9. Physical health harms  
9.1. Interpretation of physical health harms 
9.1.1. Interpretation of the physical health harms of SCRA is complicated by the 
common co-use of other substances and the number of different SCRA that 
have been misused. Individual SCRA may vary in their pharmacology and 
adverse effects but there is very limited comparative information available. 
 
9.2. Mortality  
9.2.1. Increasing numbers of SCRA-related deaths have been seen in many 
countries over the last decade [Peacock et al., 2019]. In the UK, the first 
recorded death was in 2012 and SCRA-related deaths have since increased 
substantially, with a total of 179 recorded between 2012 and 2019 in England 
and Wales where a SCRA was mentioned on the death certificate, including 
60 in 2018, and 56 in 2019 [ONS, 2020]. Given that SCRA have not always 
been tested for during investigations of deaths, actual SCRA-related death 
figures will no doubt be higher. 
 
9.2.2. NPSAD identified 179 deaths where at least one SCRA was found at post 
mortem in England between January 2012 and September 2020 (see Annex 
B). Death was considered directly related to the SCRA in 143 (84.4%) of 
these cases and was deemed to be accidental in all bar one case. NPSAD 
reported significantly higher proportions of decedents who were living in 
hostels, were of no fixed abode or incarcerated at time of death in comparison 
to all deaths reported to NPSAD from England within the same time period 
(2012 to 2020, as above). However, the largest proportion of deaths (61%) 
still involves decedents who were living in private residential accommodation. 
The majority of decedents who had a permanent address at time of death 
were living in the most deprived areas of England (deprivation deciles 1 to 3; 
72% of decedents) [English Indices of Deprivation (2019)]. Decedents were 
also older in 2018-19 than between 2012 and 2015.  
 
9.2.3. National Records of Scotland (NRS) have reported five SCRA-associated 
fatalities in deaths registered in Scotland between 2008 and 2018. In one 
case, AB-FUBINACA was found present at post mortem but was not 
implicated in the cause of death. In three cases, SCRA compounds (5F-PB-
22, AKB48, AB-FUBINACA and 5F-MDMB-PINACA) were recorded as the 
implied cause of death alongside at least one other implied substance. In the 
final case, MDMB-CHMICA was recorded as the implied and only cause of 
death, with no other substances apart from alcohol present at post mortem.  
 
9.2.4. Potential mechanisms for loss of life include cardiac dysrhythmias, seizures, 
reduced level of consciousness with impaired ventilation and loss of airway 
reflexes, central nervous system depression and liver or kidney failure. Death 
may also result from indirect causes that result from intoxication such as 
trauma or accidents. Additionally, co-misuse with other substances is 
common and these may cause or contribute to the toxicity observed [Labay et 
al., 2016; Tait et al., 2016]. Given the limited pharmacodynamic and 
pharmacokinetic data available, typical SCRA concentrations associated with 




9.3. Emergency department (ED) presentations and hospital admissions 
9.3.1. A study in Louisiana, USA, retrospectively reviewed the medical records of 
218 people presenting to three inner city emergency departments (EDs) due 
to the effects of SCRA between March and April 2014. Whilst the majority 
(75.7%) of patients were discharged directly from the ED, 12.4% and 11.5% 
were admitted for medical or psychiatric treatment respectively. The most 
common symptoms documented were hypertension, tachycardia, agitation, 
drowsiness, nausea and confusion. A cluster analysis of the reported 
symptoms demonstrated four symptom ‘clusters’ in patients presenting 
following the use of SCRA [Rowley et al., 2017]:  
• confusion, hostility, agitation;  
• nausea, vomiting, abdominal pain;  
• drowsiness; and,  
• the absence of these symptoms. 
 
9.3.2. The Euro-DEN Plus network collects information on drug-related ED 
presentations across participating centres in Europe, based on clinical 
interpretation of patient reported exposures. This study demonstrated 
increases in self-reported SCRA presentations to the EDs of the two 
participating London hospitals (St Thomas’ Hospital and King’s College 
Hospital) between 2014 and 2017. Rates of presentation at the only other 
participating UK hospital (York) were very low [EMCDDA, 2020].  
 
9.3.3. In a study of 179 patients with acute drug toxicity attending the ED at St 
Thomas’ Hospital between January 2015 and June 2015, SCRA were 
analytically identified in 18 (10%) cases. In most of these, toxicity resolved 
within eight hours and 14 patients (78%) were discharged directly from the 
ED without admission to hospital [Abouchedid et al 2017].  
 
9.3.4. An unpublished study of self-reported drug-related presentations at Bristol 
Royal Infirmary ED between May 2017 and November 2019 showed that 
‘spice’ was the second most frequent drug-related presentation after heroin, 
without consistent changes in monthly presentation numbers over the period 
of study.  
 
9.3.5. Hospital activity statistics are available for poisoning involving major drug 
groups in England [NHS, 2019] but the information collected does not focus 
specifically on SCRA. Northern Ireland, Scotland and Wales also report 
hospital admissions according to International Classification of Diseases 
codes, which places cannabis and SCRA presentations under the same 
‘cannabinoids’ category. These data are also limited by lack of analytical 
confirmation, as this is not done as part of routine clinical care. Additionally, 
coding may be inaccurate or not capture all the substances involved in the 
presentation [Wood et al., 2019]. Hospital admission data also does not 
capture the larger number of people who present to EDs and are then 
discharged.  
 
9.3.6. Hospital activity statistics for England demonstrate that poisoning caused by 
cannabis and derivatives increased from 130 in 2012/13 to 556 in 2015/16, 
subsequently falling to 363 in 2018/19. Scotland has seen a small increase in 
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cannabinoid-related hospital admissions from 23 in 2015/16 to 31 in 2017/18, 
which is thought to be due to the increasing strength of synthetic varieties 
[PHS, 2020]. These figures, however, include presentations involving 
cannabis. Equally SCRA-related admissions may also be coded in other 
poisoning categories such as ‘accidental poisoning by and exposure to other 
and unspecified drugs, medicaments and biological substances’ [NHS Digital, 
2019].  
 
9.3.7. Analysis on patient records accessing secondary and tertiary mental-health 
services across the South London and Maudsley NHS Foundation Trust 
(SLAM) evidenced that of 1,322 adults detained under Section 136 of the 
Mental Health Act between 2017 and 2018, 1.9% reported or were suspected 
of having used SCRA (all men), relative to 19.1% having used cannabis and 
11.8% cocaine. New SCRA use (defined as the first recorded use for each 
patient in the clinical database) increased steeply after 2014 to a maximum in 
the second quarter of 2016, before a small decline by the end of 2017 [Hobbs 
et al., 2020]. 
 
9.4. Poisons centre referrals 
9.4.1. Referrals to poisons centres reflect how commonly healthcare professionals 
need to seek further information about the substances that their patients may 
have been exposed to. The UK NPIS reported year-on-year increases in 
healthcare professional enquiries related to SCRA between 2011 and 2014, 
with 77% made by those working in acute hospitals. Commonly-reported 
clinical features in those reporting SCRA use without other substances 
included tachycardia (17%), reduced level of consciousness (16%), agitation 
or aggression (10%), vomiting (6.9%), dizziness (6.0%), confusion (4.8%), 
pupillary dilatation (4.6%) and hallucinations (4.6%). These reported 
exposures, however, were not analytically confirmed and the precise 
chemical compounds involved are unknown [Waugh et al., 2016].  
 
9.4.2. Reductions in annual NPIS enquiries related to NPS, of which SCRA and 
branded products likely to contain SCRA form the majority, have since been 
reported. These reductions started to occur in the year before the enactment 
of the PSA in May 2016 [Al-Banaa et al., 2020]. Unpublished information 
provided by the NPIS (see Annex C) shows that telephone enquiries related 
to SCRA, and to branded products (likely to contain SCRA), decreased from 
108 (6.7% of all enquiries relating to drugs of misuse) and 276 (17.6%) 
respectively in the financial year 2015/16 to 27 (2.4%) and 16 (1.4%) 
respectively in 2019/20. TOXBASE® is the poisons information database of 
the NPIS and reductions were also seen for TOXBASE® accesses by 
healthcare professionals to SCRA and branded products (likely to contain 
SCRA) from 5,542 (8.2% of enquiries relating to drugs of misuse) and 8,009 
(11.9%) respectively in 2015/16 to 2753 (4.0%) and 1,990 (2.9%) respectively 
in 2019/20.  
9.5. Neurological effects 
9.5.1. There have been many reports of seizures induced by SCRA use [Louh and 
Freeman, 2014]. The onset and frequency of seizures appears variable; there 
is a report of a seizure within 30 minutes of ingesting JWH-018 [Lapoint et al., 
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2011] and another following daily use of PB-22 (QUIPIC) [Gugelmann et al., 
2014]. There are also several case reports citing a high seizure frequency 
from confirmed use of MDMB-CHMICA [Hermanns-Clausen et al., 2018; Hill 
et al., 2016] or other indazole SCRA [Hill et al., 2018]. 
 
9.5.2. Wider clinical review studies have highlighted that SCRA-induced seizures 
affect a small proportion of users and tend to present as single episode 
seizures. Of 1,898 SCRA exposures reported to the US poisons centres and 
recorded on their National Poison Data System between January 2010 and 
October 2010, 52 (2.25%) seizures were reported; the majority (43) were 
single episodes, although two patients developed status epilepticus [Hoyte et 
al., 2012]. In a Centers for Disease Control and Prevention (CDC) case series 
of ED visits, 14% of visits involved generalised tonic-clonic seizures [White, 
2017].  
 
In a systematic review, generalised seizure rates were reported as 3.8% (US 
poison centre series), 14% (US Emergency Departments) and 15% 
(paediatric poison centre series). Seizures affected those with analytically 
confirmed exposure to a wide range of SCRA including JWH-122, JWH-210, 
JWH-018, PB-22, BB-22, AM-2233 and 5F-PB-22 [Tait et al., 2016]. 
 
9.5.3. Acute confusion, agitation, behavioural disturbances, aggression, delirium 
and hallucinations may also occur and are discussed below under mental 
health harms.  Neurological complications were cited as an underlying cause 
of death in 3.4% of all SCRA-associated deaths in England reported to the 
NPSAD (as of August 2020). 
 
9.6. Respiratory effects 
Common and clinically important effects of SCRA intoxication include difficulty 
in breathing and respiratory depression [Weinstein et al., 2017; Akram et al., 
2019]. An observational study of analytically confirmed SCRA-related ED 
presentations reported respiratory depression in 61% of 44 cases of MDMB-
CHMICA or AB-CHMINACA toxicity [Hermanns-Clausen et al., 2018]. In a UK 
study, all three reported cases of isolated MDMB-CHMICA-toxicity developed 
a reduction in consciousness associated with respiratory depression and type 
II respiratory failure [Hill et al., 2016]. Pneumonia has also been reported as a 
consequence of SCRA use [NEPTUNE, 2015; Weinstein et al., 2017]. 
Respiratory complications were cited as an underlying cause of death in 6.1% 
of all SCRA-associated deaths in England reported to NPSAD (as of August 
2020). 
9.7. Cardiovascular effects 
9.7.1. Tachycardia (rapid heart rate) and hypertension (high blood pressure) are 
very common in patients with confirmed SCRA exposure [Tait et al 2016]. In a 
controlled administration study, increased heart rate occurred within the first 
hour of inhaling JWH-018 vapour in doses ranging from 2mg to 6.2 mg 
[Theunissen et al., 2019]. Conversely, there have been some reports of 
bradycardia (low heart rate) and hypotension (low blood pressure) from 
SCRA-induced toxicity [Hancox et al., 2020]. Other immediate cardiovascular 
effects from intoxication include palpitations and chest pain [Cohen et al., 
2012; Faircloth et al., 2012; Hermanns-Clausen et al., 2012; NEPTUNE, 
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2015; Hill et al., 2016; Labay et al., 2016; Weinstein et al., 2017; Hill and 
Dargan, 2018; Akram et al., 2019; Theunissen et al., 2019; Hancox et al., 
2020].  
 
9.7.2. There have also been case reports linking SCRA exposure to prolonged 
cardiac repolarisation (meaning the heart muscle takes longer than normal to 
recharge between beats), a condition that increases the risk of a particular 
form of ventricular tachycardia called ‘torsades de pointes’. Risks are 
expected to be higher in users who are already taking prescribed drugs that 
prolong cardiac repolarisation (e.g. some anti-depressants, mood stabilisers, 
anti-psychotics or methadone) or other illicit substances that affect cardiac 
repolarisation such as cocaine [Hancox et al., 2020]. 
 
9.7.3. More severe cardiovascular events have also been reported from exposure, 
such as acute myocardial infarction (heart attack), perimesencephalic 
subarachnoid or intracerebral haemorrhage (bleeding around or in the brain), 
middle cerebral artery occlusion (stroke), resuscitated cardiac arrest and 
sudden cardiac death [Tait et al., 2016; Wolff and Jouanjus, 2017; Shanks et 
al., 2016; Westin et al 2016; Rose et al., 2015]. These severe effects can 
occur in young people who would not usually be considered at risk of 
cardiovascular disease. For example, myocardial infarction was described in 
three males, all aged 16, after smoking the spice product ‘K2’ [Mir et al., 
2011]. Ischaemic stroke was reported in a 25-year-old man with analytically 
confirmed exposure to ADB-FUBINACA [Moeller et al., 2017] and intracranial 
haemorrhage was reported in a 31-year-old male and a 25-year-old female 
[Rose et al., 2015]. 
 
9.7.4. Cardiac complications were cited as an underlying cause of death in 6.7% of 
all SCRA-associated deaths in England reported to NPSAD (as of August 
2020) and 23% of the cases described in an international systematic review 
[Giorgetti et al., 2020a]. 
 
9.7.5. CB1 receptors are widely expressed in both the myocardium and endothelial 
smooth muscle. The apparent diversity in reported cardiovascular effects from 
SCRA intoxication may reflect differences in acute versus acute-on-chronic 
effects, as are reported for THC [Pacher et al., 2017]. 
 
9.8. Gastroenterological effects 
Nausea and vomiting are common features of SCRA intoxication [NEPTUNE, 
2015; Labay et al., 2016; Bhanushali et al., 2013; Hermanns-Clausen et al., 
2012, Faircloth et al., 2012; White, 2017; Rowley et al., 2017] and were 
reported in 13% to 94% of presentations in a systematic review of case series 
[Tait et al., 2016]. Rare cases of cannabinoid-induced hyperemesis syndrome 
have been reported from frequent or habitual smoking of SCRA, involving 
repeated nausea, vomiting and abdominal pain [Hopkins and Gilchrist, 2013; 
Ukaigwe et al., 2014].  
 
9.9. Genitourinary and renal effects 
9.9.1. Acute kidney damage is a widely evidenced feature of SCRA toxicity 
[NEPTUNE, 2015; Hill and Dargan, 2018; Akram et al., 2019] with many 
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cases being reported in previously healthy adult males [Bhanushali et al., 
2013;Buser et al., 2014; Weinstein et al., 2017; White, 2017]. An investigation 
conducted by the Wyoming Department of Health (USA) in 2012, identified 16 
cases of acute kidney injury associated with SCRA use across six different 
US states, with no causal link to a single SCRA brand or compound across all 
the cases. SCRA exposure was confirmed analytically in six of seven cases 
tested. Renal biopsies were performed in eight patients and findings included 
acute tubular injury (five patients), acute interstitial nephritis (two patients) or 
both (one patient); five of the 16 patients were treated with haemodialysis 
[CDC, 2012].  
 
9.9.2. In addition to direct SCRA-related renal toxicity, there are other potential 
mechanisms by which SCRA can lead to acute kidney injury. Rhabdomyolysis 
(rapid breakdown of skeletal muscle) has been seen with SCRA use and this 
is one assumed mechanism of acute kidney injury [White, 2017], but renal 
toxicity may occur without elevations in creatine kinase, a key biomarker of 
rhabdomyolysis [Srisung et al., 2015]. Dehydration associated with vomiting is 
another likely cause of acute kidney injury in some cases.  
 
9.10. Reproductive effects 
Very little information is available on the effects of SCRA use during 
pregnancy. However, the developing embryo has a functioning 
endocannabinoid system and may be vulnerable, as cannabinoid signalling is 
relevant to several reproductive processes, including fertility, preimplantation 
embryonic development, oviductal embryo transport, implantation, and 
placentation [Sun and Dey, 2012; Alexandre et al., 2020]. 
 
9.11. Haematological effects 
Between March and April 2018, more than 150 patients presented to 
hospitals in Illinois, USA, with coagulopathy associated with elevation of the 
international normalised ratio after SCRA use. Analysis of serum samples 
demonstrated the presence of the long acting anticoagulant brodifacoum, 
thought to be an adulterant of the SCRA products used [Kelkar et al., 2018]. 
 
10. Neuropsychiatric health harms   
10.1. Intoxication  
10.1.1. Many SCRA are full agonists at the CB1 receptor, some with an extremely 
high affinity to the receptor binding site, producing intoxicating effects even 
after exposure to small amounts [Cohen et al., 2012]. The effects of acute 
intoxication are variable and include euphoria, paranoia, sedation or agitation, 
with or without disturbance of consciousness (i.e. delirium) [Faircloth et al., 
2012; NEPTUNE, 2015; Labay et al., 2016; Abouchedid et al., 2017]. Acute 
psychotic symptoms (i.e. hallucinations and delusions), are common effects 
of SCRA use [Weinstein et al., 2017; Hill and Dargan, 2018]. SCRA are five 
times more likely than THC to be associated with hallucinations. This may 
occur because their full agonism at the CB1 receptor inhibits GABA 
transmission [van Amsterdam et al., 2015], with downstream effects on 




10.1.2. Participants in a controlled administration study showed increased levels of 
confusion, amnesia, dissociation, derealisation, depersonalisation and 
increased drug liking after taking JWH-018 [Theunissen et al., 2019]. 
Psychotic symptoms were not observed, however, it was noted much of the 
active compound settled in the administration pipe and blood levels of 
participants were very low.   
 
10.1.3. Effect profiles are typically inconsistent between SCRA compounds, due to 
the variability of affinities to the CB1 receptor and potential activity at off-target 
receptors. This inconsistency places people at greater risk of acute toxicity as 
the compounds and doses involved are commonly unknown so effects cannot 
be predicted accurately [Peacock et al., 2019]. However, the majority of 
symptoms reported are self-limiting and of short duration [Abouchedid et al., 
2017]. Treatment of agitation and restlessness with benzodiazepines is an 
acceptable and effective intervention [Cohen et al., 2012; NEPTUNE, 2015] 
and adjunctive treatment with anti-psychotics such as quetiapine is well-
tolerated [Kalk et al., 2016], although clinicians should be mindful of the risk of 
prolonged cardiac repolarisation in SCRA users [Hancox et al., 2020].  
 
10.1.4. Data from a UK survey on SCRA use showed that users reported a shorter 
effect and faster time to peak effect than with natural cannabis [Winstock et 
al., 2013]. Similarly, users presenting for treatment in association with 
problematic SCRA use in New Zealand reported that SCRA have a short 
duration of action and quick time to peak onset of action [Macfarlane and 
Christie, 2015].  
 
10.2. Psychosis 
10.2.1. Use of SCRA has been associated with a spectrum of psychotic 
presentations, from psychotic symptoms in the context of intoxication (see 
above), to a SCRA-related psychosis that persists for weeks after intoxication 
[NEPTUNE, 2015; Akram et al., 2019; Weinstein et al., 2017; Faircloth et al., 
2012] or months [Hurst et al., 2011]. The quality of evidence is low, comprised 
mainly of case series and cross-sectional studies, often without toxicological 
confirmation of SCRA use [Hobbs et al., 2018]. Psychosis is described both in 
those with and without a preceding history of psychosis [Hobbs et al., 2018; 
Hobbs et al., 2020]. Early development of psychosis has been described after 
use of a SCRA only four times, but psychosis may also develop late, e.g. after 
more than a year of use [Hurst et al., 2011]. 
 
10.2.2. Studies of psychiatric in-patients from the USA, Israel, Turkey and Germany 
have made comparisons of symptoms between psychosis associated with 
SCRA and cannabis use [Altintas et al., 2016; Bassir et al., 2016; Shalit et al., 
2016; Welter et al., 2017]. Common themes are that patients who have used 
SCRA and experience psychosis are younger and tend to experience more 
‘positive symptoms’ of psychosis (e.g. hallucinations and delusions) than 
cannabis users, whereas cannabis users tend to show more so-called 
‘negative symptoms’ (e.g. lack of motivation, social withdrawal). Agitation, 
aggression and anxiety are reportedly more common in SCRA-related 
psychosis [Altintas, 2016; Bassir et al., 2016].  Patients who had used SCRA 
required higher daily doses of antipsychotics (mean equivalent to 11mg 
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haloperidol) than those who used cannabis (mean equivalent to 6mg 
haloperidol). Both US and UK studies have found that psychiatric patients 
with a history of SCRA use need more frequent or prolonged in-patient 
treatment than patients who do not use SCRA [Bassir et al., 2016; Hobbs et 
al., 2020]. Case reports indicate that a significant proportion of patients with 
SCRA-related or precipitated psychosis report suicidal thinking (24% in those 
without a pre-existing psychotic disorder, 40% in those with a pre-existing 
psychotic disorder) [Hobbs et al., 2018].   
 
10.3. Mood disorders  
There are less data available on mood effects with SCRA use, distinct from 
changes in effect that accompany psychosis or intoxication. Most data relate 
to mood changes in intoxication, which can range from a manic-type 
presentation, excitability, agitation and restlessness, combativeness, 
irritability to decreased activity. As reported above, suicidal thinking appears 
common [Cohen et al., 2012; Hermanns-Clausen et al., 2012; Faircloth et al., 
2012; NEPTUNE, 2015; Labay et al., 2016; Hill and Dargan, 2018].  
10.4. Memory disorders  
The controlled administration study described above revealed significantly 
impaired critical tracking and memory performance in the first hour after 
inhalation of JWH-018 [Theunissen et al., 2019]. A number of studies have 
also reported cognitive changes associated with even short or occasional 
SCRA use, including difficulty in thinking clearly, confusion, sedation and 
somnolence and memory changes or difficulties [NEPTUNE, 2015; Weinstein 
et al., 2017]. A study that tested the cognitive functioning of SCRA users at 
centres in Hungary and Israel found SCRA users to have significantly 
impaired working and long-term memory and cognitive inhibition compared to 
cannabis users and non-users [Cohen et al., 2017]. 
10.5. Anxiety  
Panic and anxiety are commonly reported effects of intoxication in user 
surveys [Faircloth et al., 2012, NEPTUNE, 2015; Weinstein et al., 2017; 
Akram et al., 2019]. Cohen et al [2017] found significantly higher anxiety 
scores for SCRA users compared to non-cannabis users.   
10.6. Psychological and physiological dependence 
10.6.1. In animal studies, prolonged exposure to SCRA results in tolerance to 
their agonist effects, decreased CB1 receptor expression and signalling in 
specific brain regions and withdrawal symptoms upon cessation of drug 
administration [González et al., 2005]. Approximately 15% of patients report 
physiological dependence [Vandrey et al., 2012] and often report withdrawal 
symptoms as the primary reason for continued use. Furthermore, withdrawal 
symptoms are sometimes reported very soon after exposure and may be 
difficult to distinguish from acute toxic effects [Rodgman et al., 2014; Cooper, 
2016]. As a result of these early symptoms, patients may feel the need to 
smoke SCRA products at least every hour [González et al., 2005]. Commonly 
reported withdrawal effects include cravings, headache, anxiety, 
anger/irritability, depression, insomnia, nausea and vomiting, loss of appetite 
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and sweating, while abrupt withdrawal may precipitate severe symptoms 
including tachycardia, chest pain, palpitations, breathlessness and seizures 
[Vandrey et al., 2012; Weinstein et al., 2017; Klega and Keehbauch, 2018] 
with the severity of withdrawal features seeming to correspond with the 
amount of SCRA used each day [Cooper, 2016].  
 
10.6.2. In a qualitative study that interviewed homeless people in Manchester city 
centre, SCRA were consistently described as more addictive than other 
substances. Interviewees reported rapid development of tolerance to SCRA 
that resulted in them using larger quantities each day. Continued use of 
SCRA was motivated by a desire to avoid the acute and unpleasant 
symptoms associated with withdrawal, despite being fully aware of the risk of 
death [Gray et al., 2020]. Symptoms of withdrawal reported by interviewees 
included hallucinations, paranoia, excessive sweating, severe stomach 
cramps, diarrhoea, vomiting and loss of appetite.  
 
10.6.3. In a study in New Zealand of patients attending treatment for problematic 
SCRA use over the course of 2013/14, heavy users reported smoking every 
one to two hours to avoid withdrawal symptoms. Symptoms reached a 
maximum at day two and remained at a high level up to day five. Many clients 
with SCRA withdrawal symptoms required intensive support including 
medication and admission to an inpatient detoxification unit. Coexisting 
substance dependence apart from nicotine dependence was low [Macfarlane 
and Christie, 2015]. The same study reported that SCRA withdrawal 
symptoms were similar to those of withdrawal from THC but were more 
severe and did not lessen with the administration of THC. The differences in 
presentation may reflect the inclusion of extraneous compounds, including 
amphetamine-like stimulants [Macfarlane and Christie, 2015]. 
11. Social harms  
11.1. Shift in demographic use 
11.1.1. While early users of SCRA may often have conformed to Newcombe’s (1999) 
definition of psychonauts, there has been a shift in demographic use of SCRA 
towards less affluent and vulnerable populations, including homeless people 
or those in prison [Blackman and Bradley, 2017]. Blackman and Bradley 
suggest that this is largely because individuals within these groupings tend to 
experience low self-esteem and minimal self-worth, with negative perceptions 
of attaining short- or long-term positive outcomes. There is a perception that 
SCRA have strong intoxicating effects, most notably their perceived 
propensity to precipitate detachment from reality [Ellsworth, 2019], which 
therefore drives people to use SCRA as an accessible and affordable way to 
release themselves from situations that are often unbearable and carry with 
them a sense of nihilism and despair. 
 
11.2. Harms to individuals who are homeless 
11.2.1. There is recognition of the high-risk behaviours precipitated by the use of 
SCRA and the exacerbation of problems experienced by the homeless 
individuals who use them. The powerful and rapidly acting psychotropic 
effects of SCRA coupled with increased accessibility and decrease in price 
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increases the risks of violence, exploitation and victimisation for the very 
vulnerable homeless population [Ellsworth, 2019]. Research focussing on use 
by young people indicated that SCRA were commonly used by the homeless 
population both to induce sleep and to ease the social and psychological 
consequences associated with living on the streets [Higgins et al., 2019].  
 
11.2.2. The Homeless Prevention leads for both Bristol, and Bath and the North East 
Somerset Council, provided anecdotal reports of dealers adopting ‘county 
line’ type tactics of coercion to supply the drug into the homeless community. 
This is where dealers target a network of potential users by pursuing 
vulnerable individuals who attend recovery groups, dependency units, and 
areas associated with those in crisis. Once the dealer establishes a 
relationship with the individual, whether through drug dependency, debt or as 
part of their ‘relationship’, they then supply drugs to the users’ associated 
peer group. Councils provided anecdotal reports of dealers with personal 
accommodation, sleeping rough in the community in an attempt to get housed 
in hostels to supply the drug (‘cuckooing’).  
 
11.3. Harms to individuals in custody  
11.3.1. The number of prisoners who report that they have developed a drug problem 
in custody has more than doubled in the last five years and SCRA are highly 
prevalent and are particularly disruptive in prisons [HM Prison and Probation 
Service, 2019]. In a study that analysed 354 non-judicial samples seized from 
Scottish prisons, 41% contained at least 1 SCRA compound. All but one of 
the SCRA detected in this study belonged to the indole/indazole-3-
carboxamide class. The concentrations of individual SCRA detected in these 
samples were up to 1.17 mg/cm2 paper. The nature of the substances present 
and their concentrations varied both between paper samples and across 
individual sheets. 
 
11.3.2. Social harms in prison resulting from SCRA use include debt, bullying, 
aggression, violence, and ‘spiking for enjoyment purposes’ [User Voice, 2016; 
Blackman and Bradley, 2017; HM Prison and Probation Service, 2019; 
Higgins et al., 2019; Corazza et al., 2020 Norman et al., 2020]. Regular users 
can develop tolerance rapidly and this can induce dependence and spiralling 
debt with dealers within prisons. In addition, bullying behaviours include 
supply based on certain conditions and targeting individuals to perform 
certain high-risk tasks. Both bullying behaviours were associated with 
relieving boredom or expressing dominance [HM Prison and Probation 
Service, 2019; User Voice, 2016]. A more disturbing aspect of SCRA use 
highlighted is that spiking individuals with high-dose SCRA has occurred to 
entertain other prisoners [HM Prison and Probation Service, 2019; Higgins et 
al., 2019]. Prisoners were provided with SCRA at no cost but were instructed 
to use an excess amount for the entertainment of other prisoners rather than 
for testing the effects of the drug for resale purposes within prison. 
 
11.3.3. A striking facet of the discussions of the negative effects of SCRA use in 
prison was the discourse provided by offenders in a prison-based study by 
Corazza et al [2020]. The majority of the language used was dark and 
punctuated with bleak metaphors, for example “going to hell’ (a hole in the 
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floor), a “dark place” (predicting one’s death), “the Devil’s drug”, and “bottom 
of the barrel” [Corazza et al., 2020].  
 
11.3.4. Scottish prison survey data from 2017 demonstrated that since the enactment 
of the PSA, there has been a decrease in prisoners reporting NPS use prior 
to entering prison but an increase of reported NPS use whilst in prison. While 
these figures are likely to be lower than the actual use of NPS and SCRA in 
prisons due to response biases, they still demonstrate a shift in the use of 
NPS in and outside prisons only a year after the enactment of the PSA 
[Norman et al., 2020].  
 
11.3.5. A smoke-free policy in Scottish prisons was implemented in July 2017, and 
was fully in effect by the end of 2018, with e-cigarette kits made available to 
inmates as an alternative. Before the smoking ban, inmates either smoked 
herbal material mixed with tobacco or would roll up a piece of the SCRA-
saturated paper into a cigarette and smoke it. Since the ban, inmates are now 
known to place pieces of SCRA-infused paper between the heating element 
and the e-liquid cartridge of the e-cigarette. The potential for differential 
effects of inhaling SCRA in this way, compared with smoking/pyrolysis, is yet 
to be explored [Norman et al., 2020]. 
 
11.3.6. A shift from SCRA-impregnated herbal materials (64% of submitted samples) 
to papers and card sprayed with, or soaked in. solutions containing SCRA 
(14% of submitted samples) has been observed in prisons in England and 
Wales. This is likely in response to the implementation of prison smoking 
bans in and to facilitate smuggling [Norman et al., 2020]. 
 
11.4. Crime, exploitation and violence 
11.4.1. Problematic use of drugs and alcohol may increase the risk of perpetration of 
interpersonal and acquisitive crimes or exacerbate the risk of falling victim to 
these offences. Gray et al (2020) identified heavy users who reported 
spending up to £50 daily, forcing them to commit crimes to fund their habit. 
Offences to pay for SCRA included low-level acquisitive crime, serious 
violence and sex work [Gray et al 2020, Higgins et al., 2019; Ralphs et al., 
2017a; 2017b]. 
 
11.4.2. Likewise, negative or unsafe environments and adverse personal 
circumstances are strongly connected with an increase in vulnerability to the 
offences above. The use of SCRA is also specifically associated with 
vulnerability to low-level acquisitive crime and offences against the person 
[Gray et al., 2020; Higgins et al., 2019]. According to Ellsworth (2019), one of 
the negative consequences of SCRA use by people who are homeless 
includes a significant ‘victimisation-enhancing’ effect. Likewise, Higgins et al 
(2019) indicated an increased risk of sexual assault experienced by female 
homeless persons who were under the influence of SCRA. The Homeless 
Prevention lead for Bristol Council provided anecdotal reports of offenders 
using spliffs or drinks spiked with SCRA to carry out sexual assaults and 
robberies. These cases are frequently not reported to the Police because 




11.4.3. Violence and aggression were also reported in the vulnerable homeless and 
prison populations because of the impact that SCRA intoxication and 
withdrawal has on mood. SCRA users reported finding themselves and others 
agitated, aggressive and violent if they were unable to obtain SCRA, with 
members of the street homeless community often inciting violence on other 
members [Gray et al., 2020]. This has also been witnessed in prisons and a 
reported increase in NPS use in prisons, predominantly SCRA, has been 
linked to an increase in violence and increased unpredictability in prisoners’ 
behaviour when under the influence of NPS [Norman et al., 2020]. 
 
11.4.4. An outbreak of adverse effects related to SCRA use in Mississippi was 
reported, where 119 patients received care in a single hospital over one 
weekend in April 2015. Of this group, 32% exhibited aggressive or violent 
behaviour. SCRA were identified in the serum of 39 of 56 serum samples 
analysed. The predominant SCRA was MAB-CHMINACA (ADB-CHMINACA), 
which was found in 33 samples [Kasper et al., 2019]. 
 
11.5. Stigma  
11.5.1. Research that focused on the pre and post legislative changes in controls of 
psychoactive drugs in 2010 indicated that some NPS (including SCRA)  were 
often used because they were easily available, less costly and there was less 
likelihood of stigma linked to a ‘drug user identity’ [McElrath and O’ Neil, 
2011; Van Hout and Brennan, 2011].  Recently, the mainstream media has 
repeatedly highlighted the devastating impact of SCRA use within the 
homeless population in Manchester. Much of this stigmatising media 
coverage has ignored the lived experiences and suffering of those whose 
lives are scarred by poverty and substance abuse [Gray et al., 2020, 
Alexandrescu, 2019]. 
 
11.5.2. In New Zealand, a study of treatment outcomes for SCRA dependency 
reported that the higher rates of admission to an inpatient setting was linked 
to the naivety of treatment staff and services about the management of SCRA 
withdrawal [Macfarlane and Christie, 2015]. 
 
11.5.3. The same has been reported in the UK. Evidence submitted by Manchester 
Metropolitan University highlighted that SCRA users had experienced 
services that underestimate the support required for this unique drug 
dependence, causing people using SCRA as their main drug not to present to 
local drug treatment services.  
12. Conclusions  
12.1. A large number of SCRA compounds have been prevalent in Europe and in 
the UK in recent years. Evidence suggests that the main location of synthesis 
is China.  
  
12.2. SCRA are typically provided as herbal smoking mixtures or sheets of paper 
sprayed with SCRA solution, which is then smoked by the user. Other 
methods of administration include vaporising (‘vaping’) SCRA liquid solutions 




12.3. Over the past five years, the most prevalent SCRA compounds identified in 
the UK are all captured by the current third generation generic control and are 
therefore classified as Class B drugs under the Misuse of Drugs Act 1971.  
 
12.4. There are examples of ‘fourth-generation’ SCRA that have been encountered 
in Europe, but these are currently not prevalent in the UK, although continued 
monitoring for their potential emergence remains important. 
 
12.5. SCRA users are most commonly males and an important minority are under 
the age of 18 years. There is evidence that the overall prevalence of NPS 
use, including herbal smoking blends (predominantly SCRA), has declined in 
the UK since 2016, with consequent reductions in poisons centre referrals. 
Deaths related to SCRA may be underestimated as these compounds may 
not be routinely tested for in drug screens. Deaths in which SCRA have been 
identified analytically increased in frequency up to 2018 and occurred more 
frequently in winter. Limited data are available after 2018. 
 
12.6. While overall population use of SCRA has declined in recent years use of 
SCRA is most prevalent in areas of high deprivation and is common in the 
homeless population and in custodial settings, driven by their 'mind-numbing' 
effects, low cost and difficulty in analytical detection.  
 
12.7. Since the ACMD last reported on these compounds, further evidence has 
emerged of the physical, mental health and social harms of SCRA. Adverse 
effects can include loss of consciousness, sometimes associated with 
respiratory depression, rapid heart rate, nausea and vomiting, agitation, 
confusion, behavioural disturbance with aggression and violence, psychosis 
and seizures. Cardiac dysrhythmias, cardiac arrest, myocardial infarction, 
stroke and acute kidney failure have also been reported. Longer term effects 
associated with SCRA use include mood disorders, anxiety, depression and 
suicidal thoughts, and there is some emerging evidence of adverse impacts 
on memory and cognition.  
 
12.8. There is also increasing evidence of pharmacological tolerance, dependence 
and withdrawal effects with SCRA use. SCRA are described by users as 
more addictive than other substances and users may need to smoke SCRA 
frequently to avoid withdrawal symptoms. Intensive support including 
medication and in-patient admission may be needed but drug treatment 
services may not be available or may not appear suitable to SCRA users.  
 
12.9. Social harms associated with SCRA use include acquisitive crime and sex 
work to fund purchase of SCRA, violence, exploitation and victimisation. 
Those under the influence of SCRA may be victims of crime, including sexual 
assaults. Use in prison may be associated with debt, bullying, aggression, 
unpredictable behaviour and violence. Prisoners may be exposed to high 
doses of SCRA, either knowingly or after surreptitious administration 
('spiking') for other inmates to be entertained by their effects. 
 
12.10. The ACMD has previously provided advice relevant to populations that have a 
high prevalence of SCRA use. These reports are ‘Drug-related harms in 
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homeless populations and how they can be reduced’ and ‘Custody-
Community Transitions (CCT)’. In these reports, recommendations were 
made by the ACMD for the Government to offer more integrated and targeted 
services to the homeless with improvements to be made in outreach and peer 
mentoring programmes in order to engage and retain homeless people in 
proven treatments. Furthermore, it has been recommended that the services 
in contact with the homeless should receive better training to obtain skills in 
dealing with complexity and in retaining homeless drug users in treatment. 
Further recommendations have also been made to reduce the stigma held by 
services providers who are employed to support people that are homeless 
and engaged in substance use. 
13. Recommendations  
No single approach will be sufficient to reduce SCRA-related harms. 
Approaches that need to be considered include legal status, surveillance, 
treatment services, education and training, and research. 
 
Classification under the Misuse of Drugs Act 
The ACMD considered different options for classification. In favour of 
reclassification to Class A, recently encountered examples have been of 
increasing potency and the severe physical and mental health impacts on 
users may be comparable to those of some Class A drugs. There have also 
been increases in SCRA-associated deaths since previous recommendations 
were made. The compounds have particularly traumatic effects on vulnerable 
communities and evidence of severe harms may be harder to find because 
use is now predominantly in marginalised populations, where data collection 
is more challenging. SCRA use may cause agitated psychosis commonly 
needing physical restraint and this may be equivalent to the effects of 
methamphetamine or crack cocaine. SCRA have a significant impact on the 
general population including young people and reclassification would give 
further powers to support law enforcement to interrupt supply.  
Arguments for maintaining SCRA in Class B are that most of the harms 
described in this report were covered by previous ACMD reports and there is 
insufficient good quality evidence of new or more severe harms to warrant a 
higher classification. While the potential impact on marginalised populations is 
a clear concern, overall population use and consequently the incidence of 
many of the harms has decreased in the last few years, suggesting that Class 
B remains appropriate. This would also prevent increased possession 
penalties for already beleaguered homeless populations. It was also 
acknowledged that one motivation for use was the reduced risk of 
detectability (i.e. in mandatory drug tests), which would not be impacted by 
reclassification. 
Having considered these arguments, the ACMD recommend that SCRA 
should remain in Class B. There was currently not enough evidence of 
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variations in harms between different examples to recommend different levels 
of classification would be appropriate for individual SCRA. 
Recommendation 1: The ACMD has reviewed the available evidence of 
harms from SCRA use and recommends that the current classification 
of all SCRA controlled by the MDA, either under the synthetic 
cannabinoid generic definition or listed by individually by name remains 
appropriate. These substances should therefore continue to be 
controlled under Class B of the Misuse of Drugs Act 1971.  
Lead: The Home Office 
Measure of outcome: SCRA continue to be included under Class B of the 
Misuse of Drugs Act 1971  
 
Scheduling under the Misuse of Drugs Regulations 2001 
Synthetic drugs interacting with the cannabinoid system or compounds 
without cannabimimetic activity that might have been captured by the ‘third-
generation’ generic definition may offer potential therapeutic benefits and the 
current Schedule 1 status of SCRA might create a barrier to research on such 
compounds of interest. However, this has largely been addressed by the 
2019 legislative changes and the ACMD will provide separate advice on 
barriers to research related to SCRA. No information is available about 
compounds captured by the ‘third-generation’ generic definition in early 
pharmaceutical development but no examples of SCRA that demonstrate 
therapeutic value or that are known to be involved in clinical trials were 
identified in this review. 
 
Research is possible involving compounds in Schedule 1, provided the 
appropriate Home Office licence is in place. The ACMD is able to review the 
appropriate schedule of specific named products when evidence has been 
obtained of therapeutic benefit. In the absence of such evidence, a change to 
Schedule 2 for the group as a whole or for any individual SCRA does not fit 
with current scheduling guidance and is therefore not recommended. 
 
Recommendation 2: The ACMD has reviewed potential uses of SCRA 
and recommends that the current scheduling of all SCRA in the Misuse 
of Drugs Regulations 2001, either under the synthetic cannabinoid 
generic definition or listed by individually by name remains appropriate. 
These substances should therefore, continue to be placed in Schedule 1 
of the Misuse of Drugs Regulations 2001 on the grounds that they 
currently have no recognised medicinal use. 
 
Lead: The Home Office 
Measure of outcome: SCRA continue to be included under Schedule 1 of 






Currently available user surveys have limited data on NPS and should be 
updated regularly to ensure that they collect data on emerging substances of 
misuse. 
At any one time, a limited number of SCRA tend to dominate the UK SCRA 
market. However, the individual types of SCRA in circulation within the UK 
have changed significantly over time, often in response to legislative changes 
in other jurisdictions. To ensure that the prevalence of SCRA is monitored, 
that analytical toxicology facilities are aware of which materials are in 
circulation and that medical practitioners are informed of which materials are 
likely to have been used, surveillance should be commissioned to monitor the 
prevalence and type of SCRA in drug seizures, waste water and in biological 
samples from users.  
There is also a need for analytical surveillance of drug and biological samples 
for accurate determination of the substances involved in episodes of misuse.  
This requires sophisticated analysis and suitable reference materials as well 
as adequate and consistent funding.  
Analysis of post mortem samples provides particularly valuable information on 
the causes of fatal drug intoxication, but the compounds that are tested for 
are inconsistent and may vary geographically. Comprehensive analysis that 
includes all possible contributing compounds is expensive and it would be 
inappropriate for this to be applied universally for all drug related deaths. 
However, it would, for example, be justified for cases where a clear 
toxicological cause of death has not been identified. Therefore, it would be 
beneficial to develop national standards for drug testing by coroners and 
procurators fiscal to improve consistency. There is also a need for information 
to be available about the specific compounds currently being misused in the 
UK to inform analysis in individual cases. 
In relation to SCRA specifically, there is an ongoing risk that compounds that 
evade the current ‘third-generation’ generic definition may be detected in UK 
drug markets in the future. The evidence does not currently suggest 
significant misuse of these ‘fourth-generation’ SCRA in the UK and those with 
CB1 agonist properties are captured by the PSA. Control of any of these 
compounds via the MDA is therefore not currently warranted, although 
ongoing monitoring for their appearance remains essential. 
To facilitate improved analytical detection, toxicology laboratories require 
assistance to underpin their ability to detect and identify SCRA. FEWS has 
previously provided this type of support to forensic drug laboratories, 
including the provision of reference materials necessary to support 
identifications in seized materials. SCRA reference materials for toxicology 
laboratories, including a wide range of metabolites and stable-isotope labelled 
materials are now available, but there are so many that obtaining a full range 
to hold as a library would be too expensive for most laboratories.  
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Recommendation 3: National user surveys should explicitly collect or 
continue to collect data on emerging substances of misuse. These 
should include the Crime Survey for England and Wales (CSEW), 
Scottish Crime and Justice Survey (SCJS), the Northern Ireland Health 
Survey series, and Smoking, Drinking and Drug use among young 
people in England (SDD) survey. 
Leads:  The Home Office, Justice Directorate (Scotland), Department of 
Health (Northern Ireland), NHS Digital  
Measure of outcome: Increased information about use of NPS subtypes 
(including SCRA) in published reports. 
Recommendation 4: Guidance on a UK-wide minimum standard set of 
post-mortem toxicology tests is developed for apparent drug-related 
deaths, to include testing for novel psychoactive substances. This 
would include agreed reporting standards. 
Leads: The Chief Coroner’s Office for England and Wales, the Coroners 
Service for Northern Ireland, the Crown Office and Procurator Fiscal Service 
Scotland, the UK and Ireland Association of Forensic Toxicologists, Faculty of 
Forensic and Legal Medicine, and local authorities. 
Measure of outcome: The development and publication of a national 
standard that facilitates a consistent approach to post-mortem toxicology 
testing in apparent drug-related deaths is taken across the UK, where 
possible.  
Recommendation 5;  
a) Toxicology analysis of samples from deaths thought to be drug-
related, where there is no obvious toxicological cause, should 
include prevalent SCRA, including ‘fourth-generation’ SCRA 
reported in global drug markets. Where this testing is not possible 
because of inadequate resources, low sample volume, or another 
reason, toxicology reports should include a clear statement that a 
SCRA test has not been carried out. If SCRA testing has been carried 
out, a list of the compounds included in the test should be included 
in the toxicology report. Information on prevalent compounds 
should be available to coroners and forensic toxicologists, who 
should take this into account when deciding on the substances to be 
tested for. Forensic toxicologists should discuss important 
limitations of their analysis in their reports to the coroner. 
b) Local partnerships undertaking learning reviews of drug related 
deaths within their populations to be clear about the extent to which 
SCRA have or have not played a role in the death. Furthermore, to 
identify any local trends and patterns, and respond accordingly to 
reduce the future incidence of harm and deaths from SCRA. 
Leads: The Chief Coroner’s Office for England and Wales, the Coroners 
Service for Northern Ireland, the Crown Office and Procurator Fiscal Service 
Scotland, the UK and Ireland Association of Forensic Toxicologists, the 
Faculty of Forensic and Legal Medicine, Public Health England (PHE), the 
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Home Office Forensic Early Warning System (FEWS), and local drug related 
deaths review partnerships. 
Measure of outcome: All post-mortem toxicology drug testing in apparent 
drug-related deaths where there is no obvious toxicological cause to include 
testing for prevalent SCRA or a clear statement that testing has not been 
done. This will enable those monitoring SCRA-related deaths to interpret case 
numbers as a percentage of those tested for SCRA. Forensic toxicology 
reports contain a clear statement about the compounds that have been tested 
for and the limitations of the analysis used should be discussed. 
Recommendation 6: The Forensic Early Warning System (FEWS) should 
provide support to improve analytical capabilities of toxicology 
laboratories nationally. Toxicology laboratories should have access to:  
(a) regularly updated information about SCRA that are currently 
prevalent in the UK, and reference materials (as provided by FEWS), 
and/or  
(b) a centralised screening service that can offer technical assistance 
when needed for the accurate identification of the SCRA present in 
relevant samples they process.  
Adequate resource should be made available to FEWS for these 
functions.  
Leads: FEWS, the Home Office 
Measure of outcome: Analytical toxicology laboratories to be able to identify 
and report on the presence or absence of currently prevalent SCRA in post 
mortem samples.   
Recommendation 7: Surveillance should be commissioned to establish 
improved systematic monitoring of the prevalence of novel 
psychoactive substances, including SCRA, in relevant samples across 
the UK. These might include:  
a) drug seizures;  
b) waste water (including targeted studies); and  
c) biological samples from users.  
This surveillance should encompass those with non-fatal toxicity, 
including those attending emergency departments, mainstream drug 
services and special or vulnerable populations, such as the homeless 
and prisoners.  
Data should be consolidated and made available to those responsible 
for the investigation of drug-related deaths as well as authorities 




Leads: Public Health England (PHE), the Home Office, the Ministry of Justice 
(England and Wales), the Department of Justice (Northern Ireland), the 
Justice Directorate (Scotland). 
Measure of outcome: Regularly published information on the prevalence of 
NPS including SCRA detected in these populations. Early detection of 
emerging NPS including SCRA to inform public health policy. 
 
Enhancing local drug treatment services 
SCRA users often do not engage with treatment services and there is a need 
for more assertive outreach to improve access to treatment within a holistic 
package of care. More assertive outreach was recommended previously by 
the ACMD in its report ‘Drug-related harms in homeless populations and how 
they can be reduced’. Opportunities should be taken to identify and refer 
clients as they present to services including emergency departments. 
Appropriate drug treatment services should be commissioned and available in 
areas where SCRA use is prevalent, with local contracts stating that this 
group is eligible for treatment as currently these services may concentrate on 
problematic heroin or alcohol use. Services also need to be provided by 
prison and probation services, providing support for prisoners with 
problematic drug use, including SCRA, while in custody and after release, as 
previously recommended in the ACMD report on ‘Custody-Community 
Transitions (CCT)’. 
Treatment services should also be aware of the burden of SCRA use 
amongst their clients. Clear referral and care pathways are needed, including 
protocols for observation or referral of those with SCRA intoxication as well as 
for the management of withdrawal, including in prisons. Tailored psychosocial 
and social care interventions should be developed and assessed and made 
available, with examples of best practice being shared. Service users who 
report psychotic symptoms or suicidal thoughts should be reviewed by an 
appropriately trained mental health professional. The prison and probation 
services of the UK should develop and extend services that provide face-to-
face, individualised support to prisoners who have drug problems in the run-
up to release and through the transition to the community. 
Recommendation 8: Assertive outreach teams should have the 
competencies and capacity to allow earlier identification and referral of 
those with problematic SCRA use. Community, residential and custodial 
treatment services should be specifically commissioned and 
appropriately funded to work with SCRA users. Treatment providers 
should survey existing clients to establish the burden of SCRA use for 
those already in treatment.  
Commissioners and treatment providers should work with other 
relevant organisations to ensure that SCRA-specific care pathways and 
structured tools are available. This should include assessment for signs 
of dependence and physical health harms, management of psychosis 
and withdrawal, and interventions to minimise the social impact of 
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SCRA use. Examples of good practice should be shared between 
services and availability and use of these tools should be audited.  
Leads:   
England  
Public Health England (PHE), the Department of Health and Social Care 
(DHSC), the Association of Directors of Public Health, Local Government 
Association (commissioners of community and residential treatment), NHS 
England (commissioners of custodial treatment), treatment providers (for 
example through Collective Voice and NHS Addictions provider alliance), 
Care Quality Commission (auditing body)  
Northern Ireland 
Public Health Agency, Health and Social Care Board (commissioners of 
community and residential treatment), South Eastern Health and Social Care 
Trust, Northern Ireland Prison Service (commissioners of custodial treatment), 
Treatment providers (through Health and Social Care Trusts), Regulation and 
Quality Improvement Authority (auditing of treatment providers)  
Scotland 
Alcohol and Drug Partnerships (commissioners of community and residential 
treatment; commissioners of treatment providers), NHS Scotland 
(commissioners of custodial treatment), Care Inspectorate (auditing of 
treatment providers) 
Wales   
Area Planning Boards, NHS, Public Health (commissioners of community and 
residential treatment), Dyfodol (G4S), Police and Crime Commissioners, NHS 
(commissioners of custodial treatment), Area Planning Boards 
(commissioners of treatment providers), NHS, third sector providers (such as 
Barod, Cais, WCADA, Kaleidoscope), Care Inspectorate Wales (auditing of 
treatment providers)  
Measure of outcome: Written management pathways available and 
practised by all providers.  
 
Training and education:  
As these compounds are most prevalent in specific communities, they may 
not be widely understood by professional staff encountering users. These 
would include staff in acute and in mental health trusts, prison staff and those 
working with homeless populations. Users themselves may also be unaware 
of the harms associated with use of these compounds. 
Recommendation 9: Training should be provided to all professional staff 
who may encounter SCRA users and delivery of this training should be 
subject to audit. Educational material should also be available that is 
tailored for SCRA users. 
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Leads: The Department of Health and Social Care (DHSC), Health Education 
England, Care Quality Commission (England), the Regulation and Quality 
Improvement Authority (Ireland), the Care Inspectorate (Scotland), the Care 
Inspectorate (Wales), the Chief Social Worker for Children and Families and 
the Chief Social Worker for adults. 
Measure of outcome: Care organisations have a training log available to 
demonstrate that relevant staff have undergone appropriate training. 
Educational material available for SCRA users. 
 
Research 
Although a substantial amount of research has been published since the 
ACMD last reviewed this group of drugs, there remain areas where further 
research would be useful to inform policy and the clinical management of 
acute and longer-term health effects. 
Recommendation 10:  Research involving SCRA should be 
commissioned, including (but not limited to) the following areas: 
- pharmacology and toxicology of prevalent and emerging SCRA; 
- optimum management of acute SCRA intoxication, including 
evaluation of potential therapies;  
- development of accurate field tests for SCRA that can adapt to 
changes in the drug market;  
- longer-term health effects of SCRA use, including effects on memory 
and cognition and on reproductive and foetal health; and 
- development and validation of structured tools for rating intoxication 
and withdrawal states. 
 
Leads: National Institute for Health Research (NIHR), Public Health England 
 
Measure of outcome: A themed topic to be developed by NIHR and any 
other relevant bodies in the next 12 months.  
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Annex A: International legal status of SCRA 
Health and Social harms from SCRA use have been witnessed across the world, 
driving demand for a political and public health response. To date, the response has 
largely been in the form of prohibition policies aimed at restricting the supply and use 
of SCRA rather than service reform [Gray et al., 2020].  
International controls 
At an international level, an increasing number of SCRA are being controlled under 
Schedule II of the 1971 United Nations (UN) Convention on Psychotropic 
Substances. Materials controlled under this Convention are set out in the annually-
updated ‘List of Psychotropic Substances under International Control’ (the ‘Green 
List’), issued by the International Narcotics Control Board (INCB). Signatories to the 
Convention are required to include all listed substances within their national system 
of control.  
Potential new materials for international control are assessed on an individual basis 
by the World Health Organisation’s Expert Committee on Drug Dependence (WHO 
ECDD). This evaluation requires a firm evidential base and only a limited number of 
substances are considered each year. When materials are added to the ‘Green List’, 
all signatories to the Convention are required to bring them under their national 
control system within six months of the announcement of the UN decision. This 
usually corresponds to an announcement by the UN in the spring of each year, 
requiring national control by the autumn.  
The December 2019 ‘Green List’ includes 14 SCRA, of which four (indicated by *) 

















The 2020 announcement of new additions to the ‘Green List’ included a further four 
SCRA, which are required to be under national control systems by autumn 2020: 
AB-FUBINACA; 
5F-AMB-PINACA (5F-AMB, 5F-MMB-PINACA); 
5F-MDMB-PICA; and 
4F-MDMB-BINACA. 
One other SCRA that was assessed, APINACA (AKB-48), was not added to the list 
but is being kept under surveillance. 
All the UN listed materials are controlled under the UK’s Misuse of Drugs Act 1971. 
National controls 
In addition to the requirement to control the materials specified by the UN 
Convention, individual countries can place other materials of national concern under 
their national control systems. This can be done either by naming individual 
substances (e.g. China), or by means of broader analogue (e.g. USA) or generic 
(e.g. UK, Germany) controls. Some relevant national responses are considered 
below. 
China 
China is widely acknowledged as the main producer and exporter of SCRA. As a 
signatory of the UN Drug Conventions, materials under UN controls are controlled 
within China. In addition, China has brought an extensive range of other NPS, 
including SCRA, under national control. The impact of these controls on production 
within China can significantly influence the range of materials encountered in other 
parts of the world. In October 2015, China placed 116 NPS under control, including 
































STS-135 (5F-APICA); and 
UR-144. 
All the listed materials are controlled under the UK’s Misuse of Drugs Act, with the 
exception of CB-13, which is reported to have poor CNS penetration. 










5F-MDMB-PINACA (5F-ADB)  
 
USA 
The USA’s system of drug control is built around two key elements:  
• the Controlled Substances Act 1970 (CSA), which individually lists controlled 
materials, and,  
• the Controlled Substance Analogue Enforcement Act 1986 (‘the Analogue 
Act’) which extends control to cover materials that are similar both in structure 
and effect to materials listed in Schedules I or II of the CSA.  
The profusion of novel structures encountered as NPS, and particularly as SCRA, 
and the requirement of the Analogue Act to be able to demonstrate similarity of 
structure to an already-controlled material, has meant that a series of additions to the 
CSA have been made which provide points of comparison for the many SCRA 
variants being identified within the NPS market.  
The CSA currently (as of May 2020) lists 42 individual SCRA as Schedule I 
materials, including 17 of the 18 of the UN ‘Green List’ materials. The US authorities 
regard the 18th material, 4F-MDMB-BINACA, as a positional isomer of 5F-AMB (5F-
MMB-PINACA) and therefore not requiring a separate entry. 






CP-47,497 and its C8 homologue; 
5F-EDMB-PINACA; 








RCS-4 and RCS-8; and 
THJ-2201 
All the US listed materials are controlled under the UK’s Misuse of Drugs Act. 
Germany 
Germany lists an extensive range of individual SCRA (more than 60) within Schedule 
II of their Federal Narcotics Act (Betaubungsmittelgesetz, BtMG). 
In addition, it has recently adopted generic controls on several types of NPS, 
including SCRA, as part of its New Psychoactive Substances Act. The German 
SCRA generic is similar to the UK’s, addressing materials made up from the four 
structural elements of typical SCRA, but is broader in scope, as it reflects some 
recently reported structural variants that are outside the UK’s current generic. 
Core structures that are covered by the German generic but not the UK’s include 
carbazole and carbolin-1-one, as well as some additional azaindole and azaindazole 
positional variants. This extends the scope of its control to cover SCRA recently 
reported by the EMCDDA such as MDMB-CHMCZCA, EG-018, EG-2201 and Cumyl-
PeGaClone.  
In addition, a separate section of the German generic covers 3-sulphonylamido 
benzoate and 3-sulphonamido benzamide-based SCRA such as QMPSB derivatives, 
a group of materials that is not addressed by the UK generic.  
Although the German generic is potentially extremely broad in scope, limitations are 
placed on the maximum size or mass of some components, which serve to limit the 
coverage of their control.   
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Annex B: Summary of most frequently identified 
SCRA in the UK 
 
Welsh Emerging Drug and Identification of Novel Substances (WEDINOS) 
Funded by Public Health Wales, WEDINOS provides laboratory testing of samples 
volunteered by the community. Samples are received anonymously by post from 
either individuals or participating organisations such as substance misuse services, 
housing and hostels, youth clubs and young people’s services, education, night clubs 
and bars, mental health community teams, local authorities, the Ambulance Service 
and the Police. Test results are then made publicly available online.  
Between January 2017 and December 2019 WEDINOS identified 19 SCRA on 623 
occasions, from 62 different post code areas. These represent 6.25% of all 
substance identifications by WEDINOS during this time period. Of these, the most 
frequently identified compounds were 5F-MDMB-PINACA (5F-ADB, 269), 4F-MDMB-
BINACA (142) and AMB-FUBINACA (118).  
Since December 2019, there has been a decrease in the number of samples 
containing AMB-FUBINACA, paralleled by an increase in the prevalence of 4F-
MDMB-BINACA. 5F-MDMB-PINACA was the sixth most commonly identified 
substance within all samples. SCRA were most frequently identified within samples 
provided by criminal justice (in particular the prison estate) and homelessness 
services [WEDINOS, 2020].  
 
TICTAC Communications Ltd.  
TICTAC is a provider of drug identification and drug information to the criminal justice 
and healthcare sectors.  For this report, TICTAC provided analysis information from 
herbal, powder and liquid products that had been test-purchased between 2015 and 
2017. These purchases were primarily from websites, but some were from shops and 
most samples purchased were herbal mixtures. Purchased samples typically 
contained more than one SCRA and the most frequently notified compounds (as a % 
of total notifications) were 5F-APINACA (35.3%), 5F-PB-22 (18.5%) and 5F-MDMB-
PINACA (5F-ADB) (8.2%, first identified in 2016).  
TICTAC also submitted analysis results from prison seizures. Many of the samples 
analysed contained more than one SCRA but the range of compounds identified was 
limited. In 2017, the most frequent compounds appearing in analysis were (as a 
percentage of total notifications) were MDMB-CHMICA (30.7%) and 5F-MDMB-
PINACA (5F-ADB) (29.4%). By 2018, this had changed to 5F-MDMB-PINACA (5F-
ADB) (46.2%) and AMB-FUBINACA (26.3%) and subsequently 5F-MDMB-PINACA 





Forensic Early Warning System (FEWS) NPS Collection Plans 
As part of the FEWS project, the Defence Science and Technology Laboratory 
(DSTL) has collected and analysed samples of suspected NPS in non-attributable 
samples 
Prison Collection Plan 
DSTL collected and analysed samples of suspected NPS in non-attributable samples 
recovered from 14 participating prison grounds between March 2018 and February 
2019. Of the NPS identifications, 99% were SCRA. The most prevalent NPS in the 
collection were 5F-MDMB-PINACA and AMB-FUBINACA, which accounted for 83% 
of the NPS occurrences. 
In the following financial year (April 2019 to March 2020) DSTL analysed 1,087 non-
attributable samples collected from 8 different prisons in Surrey, Suffolk and 
Somerset. There were 11 different SCRA identified in these samples and SCRA 
accounted for 93% of total NPS occurrences. The four most commonly identified 
SCRA (with frequency represented as percentage of total NPS notifications) were 
5F-MDMB-PICA (28%), 5F-PB-22 (23%), 5F-APINACA (5F-AKB-48) (13%) and 
APINACA (AKB48) (13%).  
UK Border Force seizures  
This collection was conducted to gather intelligence on the type and number of NPS 
that are entering the UK via Fast Parcel and postal deliveries. In its first year, the 
FEWS programme collected and analysed 149 samples from five Fast Parcel and 
postal hubs between April 2018 and February 2019. From this sample, four different 
SCRA compounds were identified, the most prevalent being 5F-MDMB-PINACA.  
The following year (April 2019 to March 2020) saw a significant reduction in samples 
received; There were 28 samples collected and analysed from a single UK Border 
Force location and in this collection three SCRA were identified (ADB-BUTINACA, 
5F-MDMB-PICA and MDMB-4en-PINACA).  
Vulnerable group collection plan 
DSTL collected and analysed samples of suspected NPS samples seized between 
March 2018 and February 2019 by the police from the homeless community and non-
attributable samples found on the premises at three Immigration Removal Centres. 
From 109 samples recovered, mostly from Immigration Removal Centres, there were 
52 NPS notifications, 35 of which were 5F-MDMB-PINACA.  
 
Eurofins 
Eurofins is a forensic service provider for the police, law enforcement agencies, 
solicitors and barristers and corporate organisations in the UK and abroad. In 
samples from police seizures between July 2019 and June 2020, three compounds 
have dominated, making up more than 75% of the notifications collectively. These 
41 
 
were 4F-MDMB-BINACA, MDMB-4en-PINACA, and 5F-MDMB-PICA, with MDMB-
4en-PINACA making up 33% of all SCRA notifications in this time period.   
 
Manchester Drug Analysis and Knowledge Exchange (MANDRAKE) 
MANDRAKE is a fixed Home Office licenced resource, based at Manchester 
Metropolitan University (MMU, Department of Natural Sciences), working in 
partnership with the Greater Manchester Police (GMP) to facilitate rapid, robust 
chemical analysis services to inform intelligence-gathering as opposed to legal action 
(i.e. prosecutions). During the period between February 2017 and February 2018, 
they tested 75 suspected SCRA herbal mixtures seized by the GMP. Across the 75 
samples, analysis frequently found three distinct SCRA present (5F-MDMB PINACA 
(5F-ADB), MDMB-CHMICA and AMB-FUBINACA), with the most prevalent SCRA 
being 5F-MDMB PINACA (appearing in 77% of the samples). These three 
compounds were largely seen on their own (in 85% of samples), but two compounds 
were sometimes found in combination (in 11% of samples) – which may be 
associated with a lack of process control during manufacture and/or blending of 
samples. Only 4% of samples contained no psychoactive or controlled ingredients. 
A wide variation in SCRA concentrations were identified across samples tested. Over 
the course of the 12-month period, analysis showed a significant decrease in the 
concentrations of samples seized. For example, of the eight samples of 5F-MDMB 
PINACA (5F-ADB) identified in seizures (not in combination) in April 2017, the 
average concentration was approximately 35 mg/g. In contrast, of the four samples of 
5F-MDMB-PINACA (5F-ADB) identified in seizures (not in combination) in September 
2017, the average concentration was approximately 2.9 mg/g. 
 
LGC Group  
The Sport and Specialised Analytical Services laboratory, part of the Standards 
division of LGC Group, formerly the Laboratory of the Government Chemist, is a 
laboratory providing specialist toxicology services in the UK. For this report it 
provided data on NPS and NPS metabolites identified from post-mortem cases with 
suspected NPS use. Samples originated from various sites across the UK including 
the Leicester Royal Infirmary Toxicology Unit, Eurofins Forensics and the Great 
Northern Hospital, Sheffield.  
In this data set the most prevalent compounds identified in post mortem cases were 
5F-APINACA (5F-AKB-48) and MDMB-CHMICA in 2015/16. From early 2016, this 
then shifted to 5F-MDMB-PINACA (5F-ADB) and AB-FUBINACA until the start of 
2019 where 4F-MDMB-BINACA and 5F-MDMB-PICA became the most frequently 
identified in analysis. This was then followed by a high prevalence of MDMB-4en-
PINACA in late 2019 and early 2020.  
It is worth noting that AB-FUBINACA, AMB-FUBINACA and EMB- FUBINACA 
converts to the same product in the body so is indistinguishable in post-mortem 
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metabolite analysis. However, due to the higher prevalence of AMB-FUBINACA in 
seizure data (as evidenced by data provided by WEDINOS, TICTAC, FEWS and 
MANDRAKE) it has been assumed that these metabolite findings were due to AMB-
FUBINACA use.  
 
The Identification of Novel Psychoactive Substances (IONA) study  
The NIHR and PHE-funded IONA study has been analysing samples from adults 
(aged 16 or over) presenting to participating hospitals in England, Scotland and 
Wales with severe acute toxicity after suspected NPS exposure since March 2015. 
By April 2020, analytical information was available for 579 study participants with 
suspected NPS exposure. In this cohort, SCRA were the most common NPS group 
identified, found in samples from 186 patients (32%).  The most common examples 
identified were 5F-MDMB-PINACA (5F-ADB, 14.7%), MDMB-CHMICA (9.8%) and 
AMB-FUBINACA (FUB-AMB, 9.7%). The proportion of patients where a SCRA was 
detected in at least one sample has reduced since 2016, with temporal changes 
differing between the most commonly identified SCRA. Reductions have been seen 
for MDMB-CHMICA since 2015, increases followed by early reductions for 5F-NPB-
22 and 5F-PB-22 (highest numbers in 2016), and increases followed by later 
reductions for 5F-ADB and FUB-AMB (highest numbers in 2017). During 2019 and 
early 2020, increasing numbers of exposures were identified involving FUB PB-22 
(QUFUBIC), 4F-MDMB-BUTINACA (4F-MDMB-BINACA), 5F-MDMB-PICA and 
MDMB-4en-PINACA. Of note, SCRA were usually found in combination with other 
drugs of misuse, with several separate examples commonly identified in samples 
from the same person, often alongside other substances. 
 
National Programme on Substance Abuse Deaths (NPSAD) 
NPSAD collates information from coroners about deaths related to drugs in addicts 
and non-addicts in England, Wales and Northern Ireland. To be recorded on the 
NPSAD database, there must be the presence of one or more psychoactive 
substance(s) directly implicated in the death, a history of dependence or abuse of 
drugs or the presence of controlled drugs at post-mortem. NPSAD receives drug-
related death reports from over 80% of coroners. Cases are recorded by year of 
death, so figures are subject to change as more reports are confirmed.  
In the years 2016 to 2018, AMB-FUBINACA and 5F-MDMB-PINACA dominated in 
drug-related-deaths in England where SCRA were detected at post mortem (see 
Table 1). This was particularly true in 2018 where these compounds made up 24% 
and 64% of the SCRA identifications in SCRA-associated deaths reported to NPSAD 
(where SCRA was either detected at post-mortem and/or implicated in cause of 
death).  
Appearance of these two substances dropped in 2019, where toxicology reports 
identified two new compounds, 5F-MDMB-PICA and 4F-MDMB-BINACA, as the most 
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prevalent SCRA found at post mortem; each accounting for 24% of the SCRA 
identifications in SCRA-associated deaths reported to NPSAD. 
 
Table 1: SCRA compounds detected at post-mortem and/or implicated in cause 
of death, in drug-related deaths in UK.  
 
  2015   2016   2017   2018   2019 TOTALS* 
  NI S E   NI S E   NI S E   NI S E   NI S E   
APINACA (AKB-
48)           1 1                         2 
BB-22     1                                 1 
AB-CHMINACA     2   1                             3 
5F-APINACA  
(5F-AKB-48)     3   1   1               1         6 
5F-PB-22 1   3      1               2       1 8 










            7   1   32   1 1 48   1  3 94 
AB-PINACA             1                         1 
MMB-CHMICA             1       1                 2 
5F-MDMB-PICA                             2       7 9 
4F-MDMB-
BINACA                             2      7 9 
APP-BINACA                             1         1 
5F-MMB-PICA                                     2 2 




                                    3 3 
MDMB-4en-
PINACA                                     1 1 
 
 
Notes for Table 1: 
 
*Figures represent the number of detections of SCRA at post mortem. Figures 
do not represent the total number of SCRA-associated deaths as there are 




** AMB-FUBINACA may also include notifications for AB- and EMB-
FUBINACA as post-mortem metabolite analysis has limited capability in 
differentiating between these compounds.  
 
(NI) Northern Ireland 
SCRA detected at post-mortem and/or implicated in cause of death in cases 
reported to the Northern Ireland Statistics Research Agency (NISRA) up until 
August 2020. Years correspond to the date the death was registered.  
 
(S) Scotland 
SCRA detected at post-mortem and/or implicated in cause of death in deaths 
registered in Scotland between 2008 to 2018. Data provided by NRS. Years 
correspond to the date of death registration.  
 
(E) England and Wales 
SCRA detected at post-mortem and/or implicated in cause of death in cases 
reported to NPSAD up until September 2020. Years correspond to the date 
the death occurred. A further 10 detections have been reported in 2020: four 
detections of 4F-MDMB-BINACA, two detections of MDMB-4en-PINACA and 
four detections of 5F-MDMB-PICA. 
NPSAD reported a single case occurring in Wales where a SCRA was 
detected at post-mortem. This was the detection of 5F-MDMB-PICA in a death 
occurring in February 2020, and as such has not been represented in the 
table above.  
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Annex C: National Poisons Information Service (NPIS) 
telephone enquiries and TOXBASE® accesses 
concerning SCRA 
 
The NPIS provides the healthcare profession in the UK with information and 
advice on the diagnosis, treatment and management of suspected poisonings 
in humans. Support is provided by the online poisons information database 
TOXBASE®, or by a 24-hour national telephone service. The NPIS can 
provide information on the number of accesses to TOXBASE® and the 
numbers and details of telephone enquiries made to the service by health 
professionals. These numbers reflect (but do not measure directly) the 
frequency of contacts between health professionals and patients presenting 
following specific suspected exposures. 
Table 2: Number (and % of all drug of misuse related activity) of 
telephone enquiries to NPIS and TOXBASE® online accesses relating to 
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 5F-APINACA (also known as 5F-AKB48 or 5F-AKB-48) 
 
Core:   Indazole 
Secondary group:  adamantyl  
Linking group:  carboxamide 
Tail:   pentyl 




Core:   Indole 
Secondary group:  an ester of 1-hydroxy-1-oxopropan-2-yl 
Linking group:  carboxamide  
Tail:   cycloalkylmethyl 





5F-MDMB-PINACA (also known as 5F-ADB or 5F-ADB-PINACA) 
 
Core:   Indazole 
Secondary structure: ester of 1-hydroxy-1-oxopropan-2-yl 
Linking group:  carboxamide 
Tail:   pentyl 
Substituents:  fluoro substituent on pentyl tail 




AMB-FUBINACA (also known as FUB-AMB and MMB-
FUBINACA)  
 
Core:   Indazole 
Secondary structure:  ester of 1-hydroxy-1-oxopropan-2-yl 
Linking group:  carboxamide 
Tail:   benzyl 
Substituents:  fluoro substituent on benzyl tail 







5F-PB-22 (5F-QUPIC or quinolin-8-yl 1-pentyfluoro-1H-indole-3-8-
carboxylate)  
 
Core:   Indole  
Secondary structure: quinolinyl  
Linking group:  carboxylate  
Tail:   pentyl 
      Substituents:  fluoro substituent on pentyl tail 
 
 
4F-MDMB-BINACA (also known as 4F-MDMB-BUTINACA) 
 
Core:   Indazole  
Secondary structure:  ester of 1-hydroxy-1-oxopropan-2-yl  
Linking group:  carboxamide  
Tail:   butyl 
Substituents:  fluoro substituent on butyl tail 







Core:   Indole  
Secondary group: ester of 1-hydroxy-1-oxopropan-2-yl 
Linking group:  carboxamide  
Tail:   pentyl 
Substituents:  fluoro substituent on pentyl tail 






Core:   Indazole 
Secondary group: ester of 1-hydroxy-1-oxopropan-2-yl 
Linking group:  carboxamide  
Tail:   alkenyl 




Annex E: Quality of evidence  
Range of evidence  
Evidence gathered was considered in line with the ACMD’s ‘Standard Operating 
Procedure (SOP) for using evidence in ACMD reports’ [ACMD, 2020].  
This report mainly draws on evidence from peer-reviewed literature (UK and 
international publications) and government reports. To evidence the prevalence of 
specific SCRA compounds identified in the UK, the ACMD’s NPS Committee wrote to 
stakeholders requesting data on their most frequently identified SCRA since 2015. 




• IONA study  
• LGC Group   
• MANDRAKE 
• NPSAD 
• TICTAC Communications Ltd  
• WEDINOS  
• NPIS  
In addition to the above, the ACMD’s NPS Committee consulted with the appropriate 
Government departments and sponsored agencies, such as MHRA, Ministry of 
Justice, the National Crime Agency (NCA) and DSTL to inform sections of the report. 
In order to identify the rates of SCRA associated-fatalities that have been recorded in 
the UK, the ACMD’s NPS Committee used a distinct list of compounds as presented 
in Table 1. The following reporting agencies for each administration were then 
approached for data on these substances: NPSAD (England and Wales), NISRA 
(Northern Ireland), NRS (Scotland). 
Quality of evidence (design, limitations, bias) 
When collating the evidence for this report, the ACMD’s NPS Committee identified a 
distinct number of limitations on the evidence identified. Retrospective analysis and 
clinical presentations frequently relied on either self-reporting of the patient or clinical 
interpretation of patient reported exposures, which mean reporting will be heavily 
influenced by the knowledge held.  
Forensic analysis on seizure materials will be limited by access to complex and 
expensive equipment, and further still by access to the appropriate reference 
material.  
It was noted that there was a distinct lack of longitudinal studies on the impact of 




Annex F: List of abbreviations used in this report 
ACMD Advisory Council on the Misuse of Drugs  
CB1 Cannabinoid Receptors Type 1 
CB2 Cannabinoid Receptors Type 2  
CCT Custody-Community Transitions 
CDC Centers for Disease Control and prevention 
CSA Controlled Substances Act 1970 
CSEW Crime Survey for England and Wales 
DHSC Department of Health and Social Care 
DSTL Defence Science and Technology Laboratory 
ED Emergency Department 
EMC Electronic Medicines Compendium  
EMCDDA European Monitoring Centre for Drug and Drug 
Addiction 
EU European Union  
FEWS Forensic Early Warning System 
GMP Greater Manchester Police 
INCB International Narcotics Control Board 
IONA Identification of Novel Psychoactive Substances study 
IUPAC International Union of Pure and Applied Chemistry 
MANDRAKE Manchester Drug Analysis and Knowledge Exchange 
MDA Misuse of Drugs Act 1971 
MDR Misuse of Drugs Regulations 2001 
MHRA Medicines and Healthcare products Regulatory Agency 
NCA National Crime Agency 
NDTMS National Drug Treatment Monitoring System  
NEPTUNE Novel Psychoactive Treatment: UK Network 
NHS National Health Service 
NIHR National Institute for Health Research 
NISRA Northern Ireland Statistics and Research Agency 
NPIS National Poisons Information Service 
NPS Novel Psychoactive Substances 
NPSAD National Programme on Substance Abuse Deaths 
NRS National Records of Scotland 
ONS Office for National Statistics 
PHE Public Health England 
PSA Psychoactive Substances Act 2016 
SCJS Scottish Crime and Justice Survey 
SCRA Synthetic Cannabinoid Receptor Agonists 
SDD Smoking, Drinking and Drug use among young people 
in England survey 
SLAM South London and Maudsley NHS Foundation Trust 




UK United Kingdom 
UN United Nations 
US The United States of America 
WEDINOS Welsh Emerging Drug and Identification of Novel 
Substances 
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ACMD membership, at time of publication 
Professor Judith Aldridge   Professor of Criminology, University of Manchester 
Dr Kostas Agath 
 
 




Chair of ACMD, Consultant psychiatrist, Central 
North West London NHS Foundation Trust 
Dr Anne Campbell  Lecturer in social work, Queens University Belfast 
Mr Mohammed Fessal  Chief Pharmacist, Change Grow Live  
Dr Emily Finch Clinical Director of the Addictions Clinical 
Academic Group and a consultant psychiatrist for 
South London and Maudsley NHS Trust  
Professor Sarah Galvani Professor of Social Research and Substance Use, 
Manchester Metropolitan University 
 
Lawrence Gibbons Head of Drug Threat (Intelligence Directorate, 
Commodities), National Crime Agency   
Professor Graeme 
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Professor of Pharmacology, University of Bristol 
Dr Hilary Hamnett Senior Lecturer in Forensic Science, University of 
Lincoln 
 
Dr Carole Hunter Lead pharmacist at the alcohol and drug recovery 
services, NHS Greater Glasgow and Clyde  
Professor Roger Knaggs Associate professor in clinical pharmacy practice, 
University of Nottingham  
Professor Tim Millar Professor of Substance Use and Addiction 
Research Strategy Lead, University of Manchester  
Mr Rob Phipps Former Head of Health Development Policy 
Branch, Department of Health, Social Services and 
Public Safety, Northern Ireland  
Harry Shapiro Director, DrugWise  
Dr Richard Stevenson Emergency Medicine Consultant, Glasgow Royal 
Infirmary  
Dr Paul Stokes Reader in Mood Disorders and 
Psychopharmacology, King’s College London  
Dr Ann Sullivan Consultant physician in HIV and Sexual health and 
National co-lead for HIV Surveillance, PHE  
Professor Matthew Sutton Chair in Health Economics, University of 
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Professor David Taylor Professor of Psychopharmacology, King’s College, 
London and Director of Pharmacy and Pathology, 




ACMD membership, at time of publication 
Professor Simon Thomas Consultant physician and clinical pharmacologist, 
Newcastle Hospitals NHS Foundation Trust and 
Professor of Clinical Pharmacology and 
Therapeutics, Newcastle University  
Dr Derek Tracy Consultant Psychiatrist and Clinical Director, 
Oxleas NHS Foundation Trust  
Ms Rosalie Weetman Public Health Lead (Alcohol, Drugs and Tobacco), 
Derbyshire County Council  
Dr David Wood  Consultant physician and clinical toxicologist, Guys 
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Dr Kostas Agath  Consultant Psychiatrist (addictions), Change Grow 
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Drug Strategy Manager for Avon and Somerset 
Constabulary   
Mr Peter Cain  Drugs Scientific Advisor 
Eurofins Forensic Services 
 
Dr Anne Campbell  
 
Lecturer in social work, Queens University Belfast 
Mr John Corkery  Senior Lecturer in Pharmacy Practice at University 
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Professor of Pharmacology, University of Bristol  
Dr Hilary Hamnett  Senior Lecturer in Forensic Science, University of 
Lincoln  
Dr Nicola Kalk Clinical lecturer in Addiction, King’s College 
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Professor Roger Knaggs   Associate professor in clinical pharmacy practice, 
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University  
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